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Abstract 
Amyotrophic lateral sclerosis (ALS) is an adult onset neurodegenerative disease 
characterised by rapid and severe motor impairments and death. Deficiency of growth 
hormone (GH), an anabolic hormone critical in linear growth and tissue repair, was 
believed to contribute to the pathology of ALS. The aim of this thesis was therefore to 
investigate the role of GH in ALS using the hSOD1G93A mouse model of ALS.  
Reflecting symptoms observed in ALS patients, my results showed a reduction in 
GH secretion in hSOD1G93A mice at the late stage of disease; establishing the hSOD1G93A 
mice as a model suitable to reflect the GH-related changes associated with ALS. 
Curiously, GH secretion increased significantly upon the onset of hindlimb weakness in 
hSOD1G93A mice, a novel finding that indicates that GH plays a more complex role in ALS 
than initially thought. The increased GH secretion was associated with skeletal muscle 
innervation at the onset of hindlimb weakness, and was hypothesised to be a protective 
mechanism to promote collateral axon sprouting: an adaptive process whereby motor 
neurons reinnervate neuromuscular junctions lost due to neurodegeneration. It was 
suggested that the protective effects of GH at the onset of hindlimb weakness may be 
driven by the upregulation of skeletal-muscle specific insulin-like growth factor-1. To 
investigate this, GH signalling was impaired in hSOD1G93A mice via cross-breeding with 
transgenic mice with truncated GH receptors. Impairing GH signalling in hSOD1G93A mice 
delayed the onset of hindlimb weakness, however did not extend survival. The 
maintenance of fat stores also appeared to be associated with delayed disease onset, 
suggesting that maintaining energy stores may be beneficial in ALS.  
Aged wild-type (WT) mice were recruited as a model of non-pathological 
neurodegeneration, and used to differentiate whether my observations in hSOD1G93A mice 
were due to pathology. Advance aged WT mice at the end of their life expectancy 
experienced significant loss of skeletal muscle innervation, but no increase in GH 
secretion was observed. Furthermore, adiposity was also not altered in response to 
neurodegeneration. These results suggest the increase in GH secretion in hSOD1G93A 
mice during the onset of motor impairments is likely a response to the ALS-like pathology 
of hSOD1G93A mice.  
This thesis is the first to present the conflict of GH being utilised in a protective 
mechanism against innervation loss in ALS, but also the potential importance of fat to 
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sustain motor function – which is potentially utilised and lost at an accelerated rate as a 
result of the increased secretion of GH. Understanding this delicate balance may reveal 
information to improve not only diagnostics and prognostics, but also the treatment of ALS. 
Observations that impairing GH receptor signalling delayed the onset of motor 
impairments also suggested the potential of GH antagonists in ALS treatment. 
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1 Chapter 1: Introduction and literature review 
1.1 Introduction 
Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease or Lou Gehrig’s 
disease, is an adult onset neurodegenerative disease. ALS is a detrimental disease that 
not only causes distress and ultimately death to the patients, but also severely impacts the 
patients’ families and community. Despite being identified close to 200 years ago, there is 
still very little known about its cause and pathology. In addition, there is currently no cure 
or an effective treatment for ALS, making the need to better understand the disease a 
pressing objective. It is currently known that ALS involves the death of neurons in the brain 
and spinal cord that controls voluntary skeletal muscle movement, as well as the 
degeneration of the skeletal muscles themselves. The question I pose in this thesis is 
whether this degenerative process can be arrested or even reversed. One possible 
approach to answer this question is to understand the role and impact of growth factors. 
Growth factors are peptides or proteins released by the body to promote growth and 
survival of cells. One such growth factor is growth hormone (GH), which is released from 
the pituitary gland to promote the development of muscles and overall linear growth. ALS 
patients have been shown to exhibit GH deficiency during the latter stages of disease, 
suggesting a link between ALS and changes to growth factors. The goal of this thesis is to 
investigate the significance of GH in ALS to better the understanding of its pathology, and 
explore the therapeutic potential of GH.  
 
1.2 Literature review 
The clinical and pathological features of amyotrophic lateral sclerosis (ALS) as a distinct 
neurological disease was first described by Jean-Martin Charcot between 1865 and 1869 
(Rowland, 2001). The term “amyotrophic lateral sclerosis” was officially coined by Charcot 
in 1874, which is derived from the clinicoanatomical observations of the weakening and 
loss of muscle -“amyotrophic”, and the hardening of the lateral columns of the spinal cord 
post mortem - “lateral sclerosis”, where gliosis follows degeneration of the corticospinal 
tracts (Rowland and Shneider, 2001). Specifically, ALS is characterised by the 
degeneration of motor neurons – efferent nerve fibres that connect the motor centres of 
the brain to voluntary skeletal muscles (Carrì et al., 1997, Jung et al., 2001, Pradat et al., 
2010). Activation of motor neurons stimulates movement (Carrì et al., 1997, Jung et al., 
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2001, Pradat et al., 2010). The loss of motor neurons in ALS is associated with 
progressive muscle atrophy and severe motor impairments - including muscles involved in 
breathing - which is ultimately fatal (Dupuis et al., 2004a, Mitchell and Borasio, 2007, 
Morselli et al., 2006). 
 
ALS is a multifactorial disease, displaying defects in neuronal physiology, 
morphology and signalling (Kiernan and Hudson, 1993, Vucic et al., 2008, Zanette et al., 
2002), skeletal muscle morphology and physiology (Holzbaur et al., 2006, Leger et al., 
2006), oxidative stress (Comi et al., 1998, Muller et al., 2007, Przedborski et al., 1996), 
immune responses (Woodruff et al., 2014, Almer et al., 2001, Almer et al., 2002), and 
energy homeostasis (Bouteloup et al., 2009, Desport et al., 2001, Desport et al., 2005, 
Dupuis et al., 2004b, Dupuis et al., 2011). While the aetiology of ALS is still largely 
unknown, genetic inheritance has been identified to be a significant contributor. In some 
prospective studies in which genealogies have been actively investigated, 17–23% of 
patients are considered familial (fALS), where patients have a family history; the remaining 
are considered sporadic (sALS), and appear to occur spontaneously (Andersen and Al-
Chalabi, 2011). Environmental factors such as algal toxins (Cox et al., 2009, Pablo et al., 
2009), and smoking (Sutedja et al., 2007, Kamel et al., 1999) have also been shown to 
contribute to the development of ALS. Yet, despite significant advances in our 
understanding of the risks and pathology associated with ALS, the cause of ALS is still 
unknown. ALS is currently incurable, and the only official pharmacological treatment is 
Riluzole (Miller et al., 2012). Riluzole, however, only prolongs survival by up to three 
months, and its therapeutic actions are poorly understood (Miller et al., 2012). The focus in 
ALS research is therefore to further understand the pathology underlying the disease, and 
identify factors that can lead to better therapeutics. 
 
This thesis reports my findings regarding the role of growth hormone (GH) – a 
hormone which influences growth and energy homeostasis – in a mouse model of ALS. I 
demonstrated significant alterations to GH secretion throughout the ALS-like disease 
symptoms of the ALS mouse model. The change in GH secretion in the ALS mouse model 
was associated with pathological changes to skeletal muscle innervation and disease 
progression. Suppressing GH signalling delayed the onset of hindlimb weakness in the 
ALS mouse model, demonstrating that GH signalling impacts the development of paralytic 
symptoms. These results also suggested that ALS is not only characterised by GH 
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deficiency, as was shown in previous studies. The novel findings that GH secretion and its 
associated factors are changed dependent on disease stage provided a new perspective 
on how GH may be utilised in therapy. In addition, dramatic increases to GH levels and its 
associated factors at the onset of hindlimb weakness may implicate novel early diagnostic 
markers. 
 
1.2.1  The clinical limits of ALS: Symptoms, Diagnosis, Prevalence, Treatment, and 
Prognosis 
ALS currently affects approximately 8.7 per 100,000 people in Australia (Economic 
analysis of motor neurone disease in Australia, 2015). The median survival is within 2-5 
years following diagnosis, however can range from months to decades (Rowland and 
Shneider, 2001, Mitchell and Borasio, 2007,  Australian mortality rates for motor neurone 
disease (ICD10 G122) as the underlying cause of death., 2013). The large variation in time 
of onset and length of survival makes an accurate prognosis difficult. In addition, late 
diagnosis – thus delayed medical management – is also predictive of shortened survival in 
ALS (Stambler et al., 1998). As such, the proper diagnosis of ALS is vital to the early onset 
of therapy and extension of health span. However, the pathology and aetiology of ALS is 
still ill-defined, therefore an accurate and globally accepted diagnosis of ALS has been 
near impossible in the past. To address the lack of international criteria for diagnosis of 
ALS, the ‘El Escorial World Federation of Neurology Criteria for the Diagnosis of 
Amyotrophic Lateral Sclerosis’ (EEC) was devised (Brooks, 1994). The EEC outlines the 
criteria and process of distinguishing ALS from other neurological diseases, and the 
degree of certainty in which the presented symptoms permit. The diagnosis of ALS 
according to the EEC requires the presence of both upper and lower motor neuron 
degeneration. The loss of lower motor neurons (LMNs) can manifest into fasciculations 
(brief spontaneous, uncoordinated contraction of a select number of muscle fibres), 
cramps, and muscle atrophy and weakness (Brooks, 1994). The loss of upper motor 
neurons (UMN) leads to spasticity (continual, uncontrollable contractions), and 
hyperreflexia and other dysreflexias (Brooks, 1994, Brooks et al., 2000). The degree of 
UMN and LMN involvement varies widely in patients, as is the rate of progression (Gordon 
et al., 2013, Turner et al., 2010, Brooks, 1994, Brooks et al., 2000). To detect and rate the 
degree of motor neuron degeneration, clinical neurophysiological methods are currently 
the core diagnostic tools of ALS to detect clinically non-apparent motor system 
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involvement (Inghilleri and Iacovelli, 2011, Li et al., 1991, Brooks, 1994). There are three 
major clinical neurophysiological methods employed to diagnose ALS: electromyography, 
nerve conduction studies, and transcranial magnetic stimulations (Brooks, 1994, Inghilleri 
and Iacovelli, 2011). Electromyograms (EMGs) measure the electrical activity of skeletal 
muscles, and can be used to determine LMN axonal loss (Inghilleri and Iacovelli, 2011). 
Diagnostic criteria include ongoing denervation, chronic partial reinnervation (an indicator 
of collateral or terminal axon sprouting), neurogenic fasciculations, and absence of 
evidence suggesting other diseases (Inghilleri and Iacovelli, 2011, Brooks, 1994). The 
limitation of EMG in diagnosing ALS is that it requires evidence of progressive spread of 
signs and symptoms (Brooks, 1994). The need to track progressively worsening symptoms 
then delays the initiation of targeted treatment. Nerve conduction studies (NCS) utilise 
electrical stimuli on motor and sensory nerves, and measure the response (Inghilleri and 
Iacovelli, 2011). Reduced values in NCS reflect axonal degeneration (Inghilleri and 
Iacovelli, 2011). The use of NCS are typically used to rule out other diseases that may 
mimic early ALS (Inghilleri and Iacovelli, 2011), but does not provide definitive diagnoses. 
Finally, transcranial magnetic stimulations (TMS) send brief, powerful magnetic pulses to 
induce electric currents within the cerebral cortex, in which the response can be measured 
in skeletal muscles. The primary function of TMS is to assess upper motor neuron function 
and involvement, and aid in the diagnosis of UMN dysfunction. The common diagnostic 
criteria for ALS in all current diagnostic methods is the necessity to eliminate the possibility 
of other diseases (Brooks, 1994). This reveals the inadequacies of our understanding of 
ALS, thus resorting to a process of elimination to diagnose ALS. New diagnostic and 
prognostic biomarkers therefore need to be discovered to accelerate the clinical diagnosis 
of ALS and maximise treatment efficacy. 
An obstacle in the early detection and diagnosis of ALS is its heterogeneity, 
particularly the site of onset and rate of progression. The site of disease onset can 
manifest in different parts of the body, and commonly divided into limb onset and bulbar 
onset (Gordon, 2013, Turner et al., 2010). The majority of patients experience limb onset, 
predominantly in the arms (Gordon et al., 2013, Turner et al., 2010, Chio et al., 2009). 
Early signs of limb onset include loss of dexterity, weakness, difficulty walking, and other 
gait abnormalities (Gordon, 2013, Turner et al., 2010, Brooks, 1994, Brooks et al., 2000). 
Patients may also experience bulbar onset, in which cranial nerve damage manifests first 
(Gordon, 2013, Turner et al., 2010, Ludolph et al., 2015). Bulbar onset manifests as 
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dysarthria (difficulty articulating speech), dysphagia (difficulty eating), and dyspnoea 
(difficulty breathing) (Gordon, 2013, Chen and Garrett, 2005, Carpenter et al., 1978, 
Janzen et al., 1988, Brooks, 1994). The region of onset is a key determinant of prognosis, 
with bulbar onset patients progressing quicker on average (Gordon, 2013, Carpenter et al., 
1978, Chen and Garrett, 2005, Turner et al., 2010, Chio et al., 2009). Taken together, the 
heterogeneity of ALS makes detection during early onset extremely difficult, implying 
patients will usually need to be experiencing noticeable impairments before proper clinical 
diagnoses can be made.  
There is currently no cure for ALS. Riluzole is the only approved medication that 
has shown efficacy in prolonging life of ALS patients (Bensimon et al., 1994, Lacomblez et 
al., 1996). Riluzole treatment of patients under the age of 75 years whom have had the 
disease for less than 5 years, and a forced vital capacity (FVC) greater than 60%, prolongs 
median tracheostomy-free survival up to approximately 3 months (Bensimon et al., 1994, 
Lacomblez et al., 1996). This marginal delay in survival is, however, coupled to potential 
side effects. Side effects range from liver damage (Lacomblez et al., 1996, Bensimon et 
al., 1994), reduced lung function (Lacomblez et al., 1996), and anorexia (Lacomblez et al., 
1996), to relatively minor disturbances such as nausea (Lacomblez et al., 1996), asthenia 
(Lacomblez et al., 1996, Bensimon et al., 1994), abdominal pain (Lacomblez et al., 1996, 
Bensimon et al., 1994), malaise (Lacomblez et al., 1996), and dizziness (Lacomblez et al., 
1996). Ultimately, while Riluzole is far from an effective treatment, it is the only medicinal 
therapeutic option for ALS patients.  
In summary, our current understanding of both the aetiology and pathology of ALS 
is severely lacking, leading to inadequacies in both the diagnosis and treatment of ALS. 
Current diagnostics for ALS require extensive testing and elimination of all other possible 
diseases. This process not only necessitates patients to develop significant impairments 
before a definitive diagnosis can be made, but also delays treatment to a rapidly 
progressing disease where early intervention is critical. In light of these challenges, 
advances need to be made in our understanding of ALS in order to develop defining 
clinical criteria for ALS which also do not require the development of debilitating 
degenerative symptoms. A possible strategy would be to expand the diagnostic and 
prognostic parameters beyond electrophysiology. Circulating factors, such as hormones 
and metabolites, serve as ideal candidates as disease markers due to their accessibility 
through standard blood, urine, or saliva testing. Assessment of circulating factors is also 
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less time consuming compared to the aforementioned electrophysiological methods. In 
addition, these hormones and metabolites themselves may be critical in understanding the 
underlying pathology of ALS, and ultimately the development of a treatment or cure. The 
intention of this thesis was therefore to identify the role and pathological changes to GH 
and its associated hormones and metabolites, thus determining their potential as 
diagnostic markers and use in therapy. 
 
1.2.2 Developing Non-human experimental surrogates: Mice models of ALS 
The diagnosis and treatment of ALS with current technology and knowledge is limited, the 
research into better understanding of the disease and drug development is thus 
paramount. While invaluable, information gained from patients is limited. These limitations 
included the lack on controllable variables – such as diet, activity, lifestyles – and data 
impractical to acquire in human patients – such as presymptomatic phenotype, high 
frequency sample collection, terminal data and tissue collection. As such, the use of 
accurate animal models are a necessity to investigate the complexities of ALS pathology 
under controlled conditions. The increase of genes identified to be associated with ALS 
has led to the proliferation of genetically-modified (GM) animal models. Of these genes, 
the human superoxide dismutase 1 (hSOD1) gene was the first to be associated with ALS 
and developed into a transgenic animal model (Rosen et al., 1993). Superoxide dismutase 
1 (SOD1) or superoxide dismutase [Cu-Zn] is an antioxidant enzyme responsible for 
catalysing the disproportionation of superoxide to hydrogen peroxide and dioxygen 
(McCord and Fridovich, 1968, McCord and Fridovich, 1969). In 1993, Rosen et al. 
identified mutations in the SOD1 gene associated with fALS patients (Rosen et al., 1993). 
To date, 166 mutations of the SOD1 gene have been identified in a subset of ALS 
patients, both in fALS and sALS (Kuźma-Kozakiewicz et al., 2013, Renton et al., 2014). 
Transgenic replacement and over-expression of the hSOD1 gene into animals has led to 
numerous successful animal models that exhibit ALS-like phenotypes, which are today 
employed to aid in ALS research. Current model animals include roundworms 
(Caenorhabditis elegans)(Wang et al., 2009), fruit flies (Drosophila melanogaster)(Watson 
et al., 2008, Ratnaparkhi et al., 2008), zebrafish (Danio rerio)(McGown et al., 2013, 
Ramesh et al., 2010), swine (Yang et al., 2014a, Chieppa et al., 2014, Yang et al., 2014b), 
and rodents (Dobrowolny et al., 2008, Jaarsma et al., 2001). Due to its small size, high 
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reproductive rate, and accurate replication of patient symptoms and progression, the 
hSOD1 mouse models have until now been the most commonly used models of ALS; in 
particular the hSOD1G93A strain. hSOD1G93A mice over-express the mutated human SOD1 
gene (Scott et al., 2008), which leads to a delayed hindlimb onset phenotype (Lee et al., 
2013, Gurney, 1997, Gurney et al., 1994).  
 
1.2.2.1 Superoxide dismutase-1 and ALS  
The advantage of identifying genes causative to ALS is the ability to extrapolate pathology 
by understanding the native gene itself. As such, to investigate the pathology of ALS 
patients, and animal models carrying the SOD1 mutations, one must first understand the 
role of SOD1. Superoxide (O2−) is a highly toxic anion by-product of mitochondrial 
respiration (Chance et al., 1979). Superoxide dismutase is the first line of defence against 
superoxide toxicity (McCord and Fridovich, 1968, McCord and Fridovich, 1969). The 
purpose of SOD1 is superoxide dismutation: catalysing the conversion of the highly 
reactive superoxide into the less reactive hydrogen peroxide (H2O2): Cu+-SOD + O2− + 
2H+ → Cu2+-SOD + H2O2 (McCord and Fridovich, 1968, McCord and Fridovich, 1969). 
SOD1 is a 17 kDa protein present in the cytosol and mitochondrial intermembrane space 
as a homodimer, poised to respond directly to the superoxide generated from the 
mitochondria (Okado-Matsumoto and Fridovich, 2001, Jaarsma et al., 2001). hSOD1 
mutations currently account for ~15% of fALS (Pramatarova et al., 1995, Rosen et al., 
1993) and 1-7% of sALS (Jackson et al., 1997, Jones et al., 1994, Gellera et al., 2001). 
There were previously two prevailing hypotheses for how SOD1 mutation causes ALS: 
loss of function and toxic gain of function. The loss of SOD1 dismutase function theory 
suggests that mutations of the SOD1 gene leads to the diminishment of the dismutation 
ability of the SOD1 enzyme, leading to uncontrolled superoxide production and 
subsequent damage (Dupuis et al., 2004a, Tsuda et al., Robberecht et al., 1994, 
Przedborski et al., 1996). However, this theory has been disproved, as SOD1 elimination 
did not result in motor neuron disease-like symptoms in mice (Reaume et al., 1996, Bruijn 
et al., 1998, Shefner et al., 1999). Yet mice lacking SOD1 do seem to suffer from 
premature ageing, and fragile neurons: suggesting normal SOD1 function is still vital to 
normal neuronal development (Reaume et al., 1996, Shefner et al., 1999). The dominant 
theory behind the SOD1-associated ALS is a toxic gain of function of the SOD1 mutation. 
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Numerous studies have explored the nature of the toxicity of the mutant SOD1 enzyme in 
ALS. The research direction in these studies can be categorised into i) increase reactive 
oxygen species generation, and/or ii) protein aggregation (Yim et al., 1990, Yim et al., 
1996, Wang et al., 2003, Molnar et al., 2009, Galaleldeen et al., 2009, Ferrante et al., 
1997, Crow et al., 1997, Banci et al., 2007). Briefly, mutation of the human SOD1 gene 
leads to protein misfolding of the SOD1 enzyme (Galaleldeen et al., 2009, Jackson et al., 
1997, Molnar et al., 2009). The misfolding of the SOD1 enzyme leads to an increase in the 
secondary peroxynitrite production of SOD1, which is catalysed by the reaction of 
superoxide with nitric oxide (O2− + NO → ONO2−) (Crow et al., 1997, Beckman et al., 
1993). Though a defensive mechanism against superoxide, peroxynitrite leads to 
irreversible nitrations to protein-bound tyrosines, a permanent modification that can 
adversely affect protein function (Crow et al., 1997). Protein aggregation has also been 
proposed as a potential underlying cause of ALS. Bunina body (small, eosinophilic 
neuronal inclusions) and Lewy body-like hyaline inclusions (round eosinophilic cytoplasmic 
inclusions consisting of cores and halos) are found in motor neurons of ALS patients 
(Bunina, 1962, Kato et al., 1989, Sasaki et al., 1989, Mizusawa, 1993). Protein aggregates 
in neurons of mutant SOD1-linked ALS patients and mice models are frequently observed 
to incorporate the mutant SOD1 protein (Koide et al., 1998, Durham et al., 1997, Wang et 
al., 2002, Watanabe et al., 2001, Johnston et al., 2000, Bruijn et al., 1998). The 
mechanism underlying the detrimental effects of these protein aggregates, however, are 
not currently well understood. 
 
While our understanding of how SOD1 may cause ALS has progressed, we have 
yet to use this knowledge to develop an effective therapy. Administering antioxidants such 
as vitamin C (ascorbic acid), vitamin E (α-tocopherol), L-deprenyl (selegiline), N-
acetylcysteine, and dehydroepiandrosterone under various regimens have been trialled to 
counteract the adverse effects of oxidative stress, however current attempts have shown 
no significant benefit to ALS patients (Orrell et al., 2008). A potential shortcoming of 
employing anti-oxidants as a therapeutic approach is that these compounds may not 
reverse muscle and neuronal loss. Repairing the degenerative damage should therefore 
be a priority in ALS treatment. I therefore propositioned, in addition, the catalysis of growth 
and repair as a therapeutic focus in ALS. 
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1.2.3 Countering degeneration: Growth Factors and ALS 
Amyotrophic lateral sclerosis is a disease characterised by the degeneration of neuronal 
tissue and skeletal muscles. The ultimate goal for ALS treatment would therefore be to 
reverse or halt the degenerative process. The growth and repair of tissues is regulated by 
growth factors (Ornitz and Itoh, 2001, Rotwein, 1991, Yancopoulos et al., 2000, Roberts 
and Sporn, 1993, Maiter et al., 1988, Martin et al., 1997, Mavalli et al., 2010, Musey et al., 
1993, Niccoli and Partridge, 2012, Oh et al., 1993, Olivecrona et al., 1999, Poesen et al., 
2008, Rhodes and White, 2002, Schindler and Darnell, 1995, Storkebaum and Carmeliet, 
2004). Dysregulation of growth factors have been associated with various degenerative 
diseases (Niccoli and Partridge, 2012, Spielman et al., 2014, Storkebaum and Carmeliet, 
2004, Wang et al., 2007, Wijesekera and Leigh, 2009). Growth factors that drive the 
growth and maintenance of neural and muscle tissues may therefore contribute to the ALS 
pathology. The manipulation of growth factors may then reverse, or at least hinder, the 
progression of disease. In this thesis, I explore the role of growth hormone and its 
associated growth factors in ALS, and discuss how my findings may benefit ALS patients. 
 
1.2.3.1 Growth Hormone and Growth 
Growth hormone is an anabolic hormone most noticeable for its role in linear growth 
(Mavalli et al., 2010, Møller and Jørgensen, 2009, Iida et al., 2004, Brooks and Waters, 
2010, Waters et al., 1999, Coolican et al., 1997) as well as the development and 
maintenance of skeletal muscle (Mavalli et al., 2010, Møller and Jørgensen, 2009, Iida et 
al., 2004, Brooks and Waters, 2010, Waters et al., 1999, Coolican et al., 1997). Also 
known as somatotropin, GH is a peptide hormone produced in and secreted from 
somatotrophs situated in the anterior pituitary gland (Asa et al., 2000, Andreassen and 
Oxlund, 2001, Bak et al., 1991, Beauville et al., 1992, Bratusch-Marrain et al., 1982, Bray, 
1969, Brooks and Waters, 2010, Butler et al., 1991, Clemmons, 2004, Corpas et al., 1993, 
Dietz and Schwartz, 1991, Dunger et al., 1991, Fryburg et al., 1991, Fryburg et al., 1992, 
Garcia-Aragon et al., 1992, Greenwood and Landon, 1966, Harvey et al., 2002, Hindmarsh 
et al., 1987, Kraemer et al., 1992, Lichanska and Waters, 2008, Rizza et al., 1982). The 
physiological actions of GH include the promotion of cell division, regeneration and growth, 
and regulation of energy homeostasis (fig. 1)(Asa et al., 2000, Andreassen and Oxlund, 
2001, Bak et al., 1991, Beauville et al., 1992, Bratusch-Marrain et al., 1982, Bray, 1969, 
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Brooks and Waters, 2010, Butler et al., 1991, Clemmons, 2004, Corpas et al., 1993, Dietz 
and Schwartz, 1991, Dunger et al., 1991, Fryburg et al., 1991, Fryburg et al., 1992, 
Garcia-Aragon et al., 1992, Greenwood and Landon, 1966, Harvey et al., 2002, Hindmarsh 
et al., 1987, Kraemer et al., 1992, Lichanska and Waters, 2008, Rizza et al., 1982).  
 
Figure 1: Growth hormone receptor signalling. A simplified diagram of the key 
signalling pathways of the growth hormone receptor (GHR) promoting growth and 
metabolism. Major signalling pathways include janus kinase (JAK)-induced signal 
transducer and activator of transcription (STAT), phosphoinositide 3-kinase 
(PI3K)/protein kinase 3 (Akt)/mammalian target of rapamycin (mTOR) activation, 
and tyrosine-protein phosphatase non-receptor type 11 (SHP2)-activated 
Ras/Raf/extracellular signal-regulated kinases (ERK). GHR specifically activates 
STAT1, 3, and 5. STAT1, 3, and 5 promote lipid utilisation and growth. STAT5 in 
particular stimulates the transcription of insulin-like growth factor-1 (IGF-1), a potent 
growth factor. STAT5 also promotes the transcription of suppressor of cytokine 
signalling-2 (SOCS2), a negative regulator of the GH-R signal pathway. PPAR, 
peroxisome proliferator-activated receptor gamma; LPL, lipoprotein lipase. 
 
1.2.3.1.1 The GH/IGF-1 signalling pathway 
The anabolic actions of GH can be categorised into primary (direct) and secondary effects. 
Primary effects are attributed to direct signalling cascades following the binding of GH to 
the transmembrane GH receptor (GH-R). The binding of GH leads to the dimerisation of 
GH-R (Brooks and Waters, 2010, Lichanska and Waters, 2008, Waters et al., 1999). GH-R 
dimerisation activates intracellular signals, such as janus kinase (JAK) and subsequent 
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activation of signal transducer and activator of transcription (STAT), and phosphoinositide 
3-kinase (PI3K)(fig. 1)(Mavalli et al., 2010, Brooks and Waters, 2010, Lichanska and 
Waters, 2008, Waters et al., 1999, Schindler and Darnell, 1995, Rowlinson et al., 2008). 
There are 7 members of the STAT family: STAT1, STAT2, STAT3, STAT4, STAT5a, 
STAT5b, STAT6 (Schindler and Darnell, 1995, Schindler et al., 1992, Fu et al., 1992, 
Zhong et al., 1994a, Zhong et al., 1994b, Yamamoto et al., 1994, Mui et al., 1995, Quelle 
et al., 1995, Smit et al., 1996). GH-R activation phosphorylates and dimerises STAT1, 3, 
5a, and 5b, depending on cell type (fig. 1)(Smit et al., 1997, Mavalli et al., 2010, Brooks 
and Waters, 2010, Lichanska and Waters, 2008, Waters et al., 1999, Schindler and 
Darnell, 1995, Smit et al., 1996). The STAT dimers in turn promote the transcription of 
genes regulating lipid homeostasis, cellular growth, proliferation, motility, and survival 
(Smit et al., 1997, Mavalli et al., 2010, Brooks and Waters, 2010, Lichanska and Waters, 
2008, Waters et al., 1999, Schindler and Darnell, 1995). STAT5 also promotes the 
transcription of suppressor of cytokine signalling-2 (SOCS2), which is used as a negative 
regulator of the signal pathway (Greenhalgh et al., 2002). Finally, GH binding to GH-R also 
activates tyrosine-protein phosphatase non-receptor type 11 (SHP2)(fig. 1)(Kim et al., 
2002). SHP2 in turn activates the Ras/Raf/extracellular signal-regulated kinases (ERK) 
pathway (fig. 1)(Lichanska and Waters, 2008, Rowlinson et al., 2008). Together, these 
signalling pathways facilitate the anabolic and energy metabolic pathways of GH-R.  
Secondary effects of GH refer to the changes to physiology not directly linked to 
GH-R activation. The most significant anabolic secondary effect of GH is the induction of 
insulin-like growth factor-1 (IGF-1) production (fig. 1)(Daughaday et al., 1972, Brooks and 
Waters, 2010, Lichanska and Waters, 2008, Waters et al., 1999). IGF-1 is a small 
polypeptide which acts as the major medium through which GH exerts its anabolic effects 
(Mavalli et al., 2010, Lichanska and Waters, 2008, Brooks and Waters, 2010). IGF-1 is 
produced predominantly in the liver, but also other peripheral tissue such as skeletal 
muscle (Sjögren et al., 1999, Bamman et al., 2001). The production of IGF-1 is stimulated 
when GH-induced JAK2 activation activates STAT5b, which promotes the transcription of 
IGF-1 (fig. 1)(Brooks and Waters, 2010, Lichanska and Waters, 2008, Waters et al., 1999). 
IGF-1 signals primarily through type-1 IGF-1 receptors (IGF-1R), a cell surface 
heterotetramer with intrinsic kinase activity (fig. 2)(LeRoith et al., 1995). The IGF-1R is 
comprised of two extracellular α subunits (IGF-1Rα) – containing the ligand binding 
domain, and two intracellular β subunits (IGF-1Rβ) – containing the tyrosine kinase 
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signalling domain (Oh et al., 1993). Binding of the IGF-1 to the IGF-1R activates Erk and 
PI3K pathways, further propagating cellular growth (fig. 2)(LeRoith et al., 1995)(fig. 2).  
 
Figure 2: Insulin-like growth factor-1 receptor signalling. A simplified diagram of 
the key signalling pathways of the insulin-like growth factor-1 (IGF-1) receptor 
promoting growth and metabolism. Majority of signalling pathways stem from the 
recruitment of insulin receptor substrates (IRS), then subsequent downstream 
activation. Major signalling pathways include phosphoinositide 3-kinase 
(PI3K)/protein kinase 3 (Akt)/mammalian target of rapamycin (mTOR) activation, and 
Ras/Raf/extracellular signal-regulated kinases (ERK) activation. Akt also activates 
NAD-dependent deacetylase sirtuin-1 (Sirt1), which promotes cellular growth and 
vitality, mitochondrial biosynthesis and gluconeogenesis, lipid utilisation, and insulin 
sensitivity. PTP1B, tyrosine-protein phosphatase non-receptor type 11; PPAR, 
peroxisome proliferator-activated receptor gamma; PGC1α, peroxisome proliferator-
activated receptor gamma coactivator 1-alpha. 
1.2.3.1.2 Hypothalamic regulation of the GH/IGF-1 signalling pathway 
The degree of GH signalling is determined by the amount (Zhang et al., 1999, Tenore et 
al., 1977, Shuster et al., 1995), and pattern of GH release (Barkan et al., 1989, Berg et al., 
1996, Huhn et al., 1993, Polonsky et al., 1988, Ho et al., 1988b, Maiter et al., 1988). The 
release pattern of GH is dependent on two tiers of regulating signals: hypothalamic 
regulation and feedback control. 
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Growth hormone secretion from the pituitary gland is controlled primarily by two 
opposing regulatory neuro-hormones: growth hormone-releasing hormone (GHRH) and 
somatostatin (SRIF) (fig. 3). GHRH is secreted from GHRH neurons, situated in the 
arcuate nucleus (ARC) of the hypothalamus (Balthasar et al., 2003). Once released into 
the median eminence – which connects the hypothalamus to the pituitary gland, GHRH 
travels via the hypothalamo-hypophyseal portal system to the anterior pituitary gland 
where it promotes GH production and release (fig. 3)(Lussier et al., 1991, Bilezikjian and 
Vale, 1983). GHRH serves as the primary stimulatory regulator of GH (Sam, 2008). By 
contrast, SRIF is the primary inhibitory regulator of GH, and acts to reduce both GH 
release from the pituitary gland and counteract the actions of GHRH (Bertherat et al., 
1991, Yamauchi et al., 1991). SRIF neurons are located in both the periventricular nucleus 
(PevN) and the ARC (Dierickx and Vandesande, 1979). SRIF neurons of both the PevN 
and ARC have been shown to synapse onto GHRH neurons in the ARC (Romagnano et 
al., 1982, Kawano and Daikoku, 1988, McCarthy et al., 1992), demonstrating that SRIF 
neurons can directly modulate GHRH neuron activity. SRIF neurons in the PevN also form 
projections into the median eminence (Merchenthaler et al., 1989, Kawano and Daikoku, 
1988, Dickson et al., 1994), which also releases SRIF into the hypothalamo-hypophyseal 
portal system to suppress GH release from somatotrophs (Lussier et al., 1991, Shimon et 
al., 1997, Brazeau et al., 1973). Together, the alternating prevalence of GHRH and SRIF 
result in a rhythmic pattern of GH release, where pulses of GH with defined peaks are 
released at frequent intervals separated by low-level troughs of basal secretion 
(Achermann et al., 1999, Hindmarsh et al., 1991, Mogi et al., 2004, Vance et al., 1985) 
(Tannenbaum, 1993, Ho et al., 1987, Polonsky et al., 1988, Ho et al., 1988b). This 
pulsatile release of GH is critical in its physiological effects and role in disease, such as the 
amplitude (Berg et al., 1996, Ho et al., 1987, Støving et al., 1999, Isgaard et al., 1989, 
Maiter et al., 1988), frequency (Barkan et al., 1989), and basal levels (Støving et al., 1999, 
Veldhuis et al., 1995).  
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Figure 3: Systemic influences of growth hormone and feedback mechanisms. 
Growth hormone (GH) secretion from the anterior pituitary gland is primarily 
regulated by the hypothalamic hormones: growth hormone-releasing hormone 
(GHRH) and somatostatin (SRIF). GH is also controlled by a number of 
autoregulatory mechanisms. These mechanisms include endocrine feedback of GH 
and hepatic insulin-like growth factor 1 (IGF-1) to somatotrophs and the 
hypothalamus. Release of GH stimulates development, growth, and repair of 
systemic tissue, including skeletal muscles and neurons. GH exerts its anabolic 
effects on skeletal muscles via direct stimulation or promotion of muscle IGF-1 
(mIGF-1). mIGF-1 stimulates systemic tissue in an autocrine and paracrine manner, 
promoting growth and repair. GHRH, growth hormone-releasing hormone; SRIF, 
somatostatin. 
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1.2.3.1.3 Feedback control of the GH/IGF-1 signalling pathway 
Beyond GHRH and SRIF, GH secretion is controlled by a multitude of regulatory feedback 
mechanisms. Of these, the two most important to note for this thesis are GH and IGF-1 
negative feedback loops (fig. 3). The GH feedback loops function within the anterior 
pituitary gland and the hypothalamus. Somatotrophs express GH-Rs (Fraser et al., 1991), 
and it is thought that GH acts via an autocrine/paracrine route to supress its own synthesis 
and release (fig. 3)(Wehrenberg and Giustina, 2010, Glenn, 1986, Rosenthal et al., 1991). 
Similarly, GH also modifies GHRH and SRIF neuron activity (Burton et al., 1995, Sato and 
Frohman, 1993). The process through which this occurs is currently not well understood, 
though it is speculated to involve direct feedback onto SRIF neurons, as GH-Rs are 
expressed on SRIF neurons but not GHRH neurons (Burton et al., 1995, Minami et al., 
1998). However, this direct influence of GH on GHRH/SRIF neurons seems relatively 
marginal, as only small subpopulations of GHRH/SRIF neurons appear to be activated in 
response to exogenous GH (Burton et al., 1995). This may suggest that other influential 
signals ultimately play an equal or greater role in the regulation of GH release, for example 
neuromodulators that influence neural activity and behaviour (Epelbaum et al., 1981, 
Giustina and Veldhuis, 1998, Martin et al., 1978), as well as neuropeptides and hormones 
that influence food intake and energy metabolism (Mano-Otagiri et al., 2006, Watanobe 
and Habu, 2002, Kojima et al., 1999, Watanobe and Tamura). As most of these factors 
that influence GH/IGF-1 signalling have additional functions, it is also important to account 
for these consequential effects when assessing their role in ALS, optimising the chances 
of obtaining useful information to treat the disease. 
GH-induced hepatic (liver) IGF-1 production also feeds back upon the 
hypothalamus and pituitary gland to suppress GH production (fig. 3) (Roith et al., 2001, 
Sjögren et al., 1999, Yakar et al., 1999). IGF-1Rs are expressed on SRIF and GHRH 
neurons in the hypothalamus, as well at somatotrophs in the pituitary gland (Olchovsky et 
al., 1993, Fagin et al., 1989). It has long been established that IGF-1 exposure to 
somatotrophs suppresses GH production and release (Yamashita and Melmed, 1986, 
Morita et al., 1987). This suggests that hepatic (circulating) IGF-1 acts in an endocrine 
manner to act as a negative regulator of GH secretion directly on the pituitary gland. Much 
less defined is the role of IGF-1 on the hypothalamic control of GH release. It is known that 
IGF-1 crosses the blood-brain barrier (BBB) to interact with the hypothalamus (Pan and 
Kastin, 2000). IGF-1Rs have also been shown to be expressed throughout the brain, 
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including high expression across the arcuate nucleus, ventromedial hypothalamus 
(housing the SRIF neurons), and the median eminence of the hypothalamus. The 
presence of IGF-1R in the hypothalamus, and that IGF-1 can cross the BBB indicates that 
circulating IGF-1 is capable of influencing hypothalamic activity. In the brain, IGF-1 has 
been shown to suppressed GH secretion by increasing SRIF expression while reducing 
GHRH expression (Kappeler et al., 2008, Sato and Frohman, 1993). This reduction in pro-
GH signalling also results in reductions in circulating IGF-1 and its binding proteins 
(Kappeler et al., 2008).  
In summary, as the signalling pathways of GH and IGF-1 are intertwined, with direct 
influences at the hypothalamic and pituitary level, it is paramount that investigations into 
one must be accompanied by the other. 
 
1.2.3.2 The GH/IGF-1 signalling pathway and the Nervous System 
ALS is known primarily as a neurodegenerative disease, understanding the impact growth 
factors have on neuronal growth and repair is thus critical in understanding their role in 
ALS. An acute loss of LMNs – due to trauma, acute disease, or developmental remodelling 
– normally leads to adaptive collateral axonal sprouting, a safety mechanism that ensures 
every skeletal muscle fibre maintains a presynaptic connection (Gordon et al., 2004, 
Brown et al., 1981). Collateral axonal sprouting involves the reinnervation of muscle fibres, 
which have lost their original axonal connection, by a newly formed axon from a 
neighbouring neuron (fig. 3)(Brown et al., 1981). In ALS, the chronic loss of LMNs also 
leads to axonal sprouting, which effectively masks the loss of motor neurons during the 
early stages of disease (Frey et al., 2000, Azzouz et al., 1997, Shefner and Gooch, 2002, 
Aggarwal and Nicholson, 2002, Hansen and Ballantyne, 1978). However, upon the loss of 
approximately half of the original number of motor neurons, and axonal sprouting reach 
beyond 5- to 8-fold of the original number of connections, the adaptive safety mechanism 
becomes maladaptive (Frey et al., 2000, Azzouz et al., 1997, Shefner and Gooch, 2002, 
Aggarwal and Nicholson, 2002, Hansen and Ballantyne, 1978), where further sprouting is 
compounding to the degenerative process by overwhelming the surviving neurons (Gordon 
et al., 2004). The mechanisms underlying axonal sprouting is currently unclear, though 
locally produced sprouting factors such as IGF-1 are considered to drive the process 
(Glazner and Ishii, 1995, Glazner et al., 1994, Caroni and Grandes, 1990).  
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1.2.3.2.1 The GH/IGF-1 signalling pathway and the central nervous system 
1.2.3.2.1.1 The role of GH in the central nervous system 
It is now known that neurogenesis in the central nervous system (CNS) occurs 
continuously throughout life (Christophidis et al., 2009, Kim and Sun, 2012). Neurogenesis 
drives the necessary development of the nervous system during embryonic and postnatal 
growth, as well as supporting neuroplasticity in response to normal brain function and 
trauma throughout life (Kempermann et al., 2002, Taupin, 2006). Recent studies have 
shown that neurogenesis is increased in the brain in response to injury, though the 
process is not fully understood (Parent, 2003, Jin et al., 2006).  
GH-Rs are expressed throughout the brain (Lobie et al., 1993, Harvey et al., 2002), 
and GH-R expression is high in brain regions undergoing embryonic neurogenesis 
(Garcia-Aragon et al., 1992, Turnley et al., 2002). This elevated GH-R expression is 
accompanied by an increase in GH presence in cells of ventricular zones (Turnley et al., 
2002), suggesting increased supply of GH to the CNS during neuronal growth. GH also 
plays an important role in postnatal neurogenesis, as high levels of GH-R is continually 
expressed in the brain (Lobie et al., 1993). In addition, multiple studies have demonstrated 
that elevating GH levels promote survival of immature neurons in the hippocampus (Sun 
and Bartke, 2007, Christophidis et al., 2009, Garcia-Aragon et al., 1992, Turnley et al., 
2002). In response to CNS injury, GH appears to be upregulated locally at the site injury to 
promote tissue restoration. GH levels increase in neurons, blood vessels, microglia, and 
astrocytes at and approximate to sites of traumatic injury in rats (Scheepens et al., 2001). 
Christophidis et al. (2009) also demonstrated that GH-R expression increases in 
proliferating neurons in subventricular zones of rats following hypoxic-ischemia. These 
same neurons proliferated in response to exogenous GH (Christophidis et al., 2009). In 
summary, current literature suggests that GH is important in maintaining neuroplasticity 
and promoting neurogenesis in response to injury in the CNS.  
 
1.2.3.2.1.2 The role of IGF-1 in the central nervous system 
Compared to GH, the role of IGF-1 in the CNS is much less understood. In rodents, IGF-1 
and IGF-1R mRNA and protein expression encompasses the cerebral cortex, 
hippocampus, cerebellum, brainstem, hypothalamus, and the spinal cord (Bach et al., 
1991, Werther et al., 1990, Walter et al., 1997). The expression level of IGF-I and its 
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receptor is restricted in adulthood, whilst widely distributed in the foetal and neonatal CNS 
(Bartlett et al., 1991, Garcia-Estrada et al., 1992, Werther et al., 1990, Bondy, 1991, Bondy 
and Lee, 1993a, Bondy and Lee, 1993b). Research regarding the expression of IGF-1 and 
its related proteins in the human brain have been limited. Adem et al. (1989) demonstrated 
using quantitative autoradiography to localise IGF-1 receptors in two adult (aged 56 and 
68 years) male human brains, and, similarly to rodents, found ubiquitous expression 
throughout the brain, particularly in the hippocampus, amygdala, cerebellum, and the 
cerebral cortex. Though the sample size is low in the study by Adem et al. (1989), earlier 
studies also supported the presence of IGF-1 receptors in both foetal (Sara et al., 1983) 
and adult (Carlsson-Skwirut et al., 1986, Sara et al., 1982) human brain samples. 
Together, these results suggest that the CNS may have the capacity to respond to IGF-1. 
This prompts the question whether IGF-1 may also regulate growth and repair in the CNS. 
The evidence of elevated IGF-1R expression in foetal and neonatal animals suggests that 
IGF-1 may play a significant role in early growth and development of the CNS. To better 
understand the role of IGF-1 in neuronal growth, and in particular the regeneration of 
neurons, studies have been conducted to investigate the expression of IGF-1 and its 
receptor following brain injury. Interestingly, the type of assault to the brain seems to 
dictate the role of IGF-1. Guthrie et al. (1995) induced lesions in the hippocampus of adult 
male rats, and documented the physiological response. IGF-1 mRNA expression at the 
lesion site was significantly increased 3-5 days following lesioning, and corresponded to 
axon sprouting (Guthrie et al., 1995); suggesting direct trauma to neurons in the 
hippocampus may lead to the upregulation of IGF-1. The source of the local IGF-1 
production appears to be primarily produced from surrounding glial cells (Walter et al., 
1997, Garcia-Estrada et al., 1992, Guthrie et al., 1995). In contrast, hypoxic-ischemic insult 
to the brain appears to suppress IGF-1 expression. Lee et al. (1996) demonstrated in 7-
day old mice that hypoxic exposure significantly reduced IGF-1 mRNA expression 
throughout the brain in a time-dependent manner, particularly in the thalamus and the 
hippocampus. The contrast in IGF-1 expression between brains subjected to electrolytic 
lesioning and hypoxic-ischemia appears to be related to the metabolic disturbance induced 
by the hypoxic-ischemic insult (Lee et al., 1996). During and after hypoxic-ischemia, 
oxidative metabolism in the brain is compromised due to the decreased availability of 
glucose and oxygen to the neonatal brain (Vannucci, 1993, Vannucci et al., 1994). This 
leads to a persistent loss of cellular ATP generation, which in turn impairs metabolic 
processes that require energy (Lee et al., 1996). These results suggest that while 
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assessing the role of IGF-1 (and by extension GH), the metabolic status – such as energy 
balance and substrate availability – also needs to be accounted for in addition to neuronal 
loss and damage. Moreover, the abundance of IGF-1 mRNA expression is very low 
relative to IGF-1R expression, suggesting that peripherally produced IGF-1 (and not locally 
produced IGF-1) may more likely contribute to IGF-1 signalling in the brain (Carro et al., 
2000, Trejo et al., 2001). Our understanding of how GH/IGF-1 acts on the periphery may 
therefore be more important in diseases such as ALS, where neuronal loss primarily 
affects peripheral tissues. 
 
1.2.3.2.2 The GH/IGF-1 signalling pathway and the peripheral nervous system 
Though there has been steady progression in our understanding of GH in the CNS, there 
is still very little known about the role of GH on the peripheral nervous system (PNS), and 
whether these relationships – if any – change in response to diseases such as ALS. While 
there have been studies identifying the role of GH in neuronal connections in the CNS 
(and by extension may apply to UMNs) no studies have investigated the role of GH and 
the development of LMNs and formation of neuromuscular junctions (NMJs).  
NMJs are synapses formed between motor neurons and the muscle fibers they 
innervate (fig. 4)(Sine, 2012). The quality and quantity of the NMJs determines the signal 
strength and quality from the motor neuron to the muscles, and hence motor function. 
LMNs innervating skeletal muscles stimulate muscle contractions through the 
neurotransmitter acetylcholine (ACh)(Caillé et al., 1985, Matthews and Matthews, 2002). 
ACh is stored within vesicles at the presynaptic terminal of the motor neuron, and released 
upon neuronal excitation (fig. 4)(Caillé et al., 1985, Matthews and Matthews, 2002). The 
ACh-containing vesicles are released from the active zones of the presynaptic terminal 
into the synaptic cleft (fig. 4)(Caillé et al., 1985, Balice-Gordon and Lichtman, 1990, 
Matthews and Matthews, 2002). Directly opposing the active zones on the muscle fibre are 
ACh receptors (AChRs) (fig. 4)(Caillé et al., 1985, Balice-Gordon and Lichtman, 1990, 
Matthews and Matthews, 2002). The conglomeration of AChRs form plaques mirroring the 
presynaptic active zones, in a postsynaptic specialisation known as the postsynaptic 
endplate (fig. 4)(Balice-Gordon and Lichtman, 1990); the activation of AChRs by ACh 
results in a signalling cascade which leads to the contraction of the muscle (Ebashi, 1976, 
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Bers, 1993). The development and maturity of the presynaptic terminal is dependent on 
the postsynaptic endplate, and vice versa (Balice-Gordon and Lichtman, 1990). 
 
Figure 4: Illustration of the neuromuscular junction. In response to action 
potentials propagated down the motor neuron axon, vesicles containing acetylcholine 
(ACh) are transported to the active zones of the presynaptic terminal. ACh is then 
released into the synaptic cleft, and eventually binds to ACh receptors on the 
postsynaptic endplate. The activation of AChRs leads to the contraction of the 
skeletal muscle. AChR, acetylcholine receptor. 
 
In contrast to GH, IGF-1 is documented as a potential sprouting factor that might aid 
the reinnervation of muscle. Glazner et al. (1994) reported that IGF-I mRNA expression 
was significantly increased at the distal end of sciatic nerves of rats subjected to controlled 
nerve damage. IGF-1 mRNA expression declined again following axon regeneration, 
suggesting IGF-1 is upregulated to promote axonal regeneration. Accordingly, IGF mRNA 
expression remained elevated in transected nerves where axon regeneration was 
prevented (Glazner et al., 1994). In addition, Caroni and Grandes (1990) showed that 
subcutaneous injections of IGF-1 directly above skeletal muscle induced a ten-fold 
increase in local axon sprouts compared to the contralateral vehicle-treated control 
muscle. Taken together, these results suggest that the local expression of IGF-1 in 
skeletal muscle (mIGF-1) plays a critical role in axonal sprouting (fig. 5). 
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Figure 5: Potential influences of growth hormone and insulin-like growth 
factor-1 in collateral axonal sprouting. Release of growth hormone (GH) 
stimulates development, growth, and repair of systemic tissue, including skeletal 
muscles and neurons. The role of GH and the subsequent insulin-like growth factor-1 
(IGF-1) production in collateral axonal sprouting and neuromuscular junction 
formation is currently unknown. It is also unknown how or if GH/IGF-1 signalling in 
the peripheral nervous system affects GH release. GHRH, growth hormone-releasing 
hormone; SRIF, somatostatin. 
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In summary, further investigations to the relationship between the GH/IGF-1 
signalling pathway and skeletal muscle innervation in ALS will lead to the better 
understanding of the pathology underlying the progressive neurodegeneration and the 
early compensatory mechanisms. Understanding how adaptive axon sprouting affects 
disease progression – and how it ultimately fails – may provide insights into how growth 
factors may be used to treat and cure ALS. 
 
1.2.3.3 GH/IGF-1 signalling in ALS: what we know so far 
The concept of needing to understanding the role of GH/IGF-1 signalling has mostly been 
marginalised in ALS research, primarily due to previous failed attempts at utilising GH as a 
therapeutic agent. In 2006, Morselli et al. investigated whether the GH/IGF-1 axis is 
impacted by ALS pathology. Both basal and GHRH-stimulated GH levels were reported to 
be impaired in 73% of their patients (fig. 6). 
 
 
Figure 6: Growth hormone deficiency in amyotrophic lateral sclerosis patients. 
Peak GH concentrations after growth hormone-releasing hormone (GHRH) + arginine 
administration to amyotrophic lateral sclerosis (ALS) patients and controls. The lines 
at 9 and 16 ng/ml represent the first and third percentile limits; the shaded area 
represents the predicted normal range of GH response (Reproduced from Morselli et 
al., 2006). 
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By contrast, the changes to IGF-1 release and signalling in ALS is less clear. Studies 
have reported no change (Bilic et al., 2006), increased (Pellecchia et al., 2010), and 
reduced (Wilczak et al., 2003) circulating IGF-1 levels in ALS patients. Little is known 
about the tissue-specific levels of IGF-1 in ALS patients, though there have been reports of 
reduced mIGF-1 protein expression in ALS patients (Lunetta et al., 2012). Thus, there 
appears to be a net reduction in GH/IGF-1 levels in ALS patients, suggesting that the loss 
of GH/IGF-1 signalling may contribute significantly to ALS pathology.  
Current studies investigating GH/IGF-1 signalling in ALS patients have only targeted 
the latter stages of disease, while the role of GH prior to and throughout disease 
progression remain unknown. Regardless, several attempts have been made to alter 
GH/IGF-1 actions in ALS to modify disease course. Dobrowolny et al. (2005) 
demonstrated that overexpression of mIGF-1 in hSOD1G93A mice delayed disease onset 
(111 ± 1.8 days of age vs 120.8 ± 1.0 days of age), disease progression (mean disease 
duration: 12 ± 0.6 days vs 32 ± 0.8 days), and extended survival (123 ± 1.4 days of age vs 
152.8 ± 1.4 days of age). In addition, IGF-1 overexpression in the brain of hSOD1G93A mice 
at 90 days of age significantly delayed disease progression, and extended survival (121.5 
vs 133.5 days of age)(Dodge et al., 2008). The reduction in survival extension in this latter 
study suggests that early intervention and differential sites of actions may determine the 
capacity of IGF-1 in delaying the deleterious effects of hSOD1G93A.  
 
1.2.3.3.1 GH/IGF-1 in ALS therapy 
While our understanding of the relationship between ALS and GH/IGF-1 release and actions 
remains limited, attempts at utilising GH in the treatment of ALS patients have been made 
regardless. Of these, Smith et al. (1993) and Sacca et al. (2012) conduct the largest clinical 
investigations of the potential therapeutic effects of recombinant human GH (rHGH) on ALS 
patients. Smith et al. (1993) recruited 75 patients and treated them with a thrice-weekly fixed 
rHGH regimen, whereas Sacca et al. (2012) involved 40 patients and treated them with 
progressively greater doses of rHGH with the goal of raising IGF-1 levels. Both studies 
concluded no significant differences in survival or progression between rHGH and placebo 
patients. IGF-1 has also be trialled as a therapeutic in ALS patients. Sorenson et al. (2008) 
(placebo (n = 163) vs recombinant human IGF-I (rhIGF-1) 0.1 mg/kg/day (n = 167)) and 
Borasio et al. (1998) (placebo (n = 59) vs rhIGF-I 0.1 mg/kg/day (n = 124)) delivered rhIGF-
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1 subcutaneously to ALS patients in attempt to investigate the therapeutic efficacy of IGF-1; 
both studies showed no significant improvements to disease progression nor tracheostomy-
free survival. A critical limitation of both studies, however, is that the bioavailability of 
subcutaneously delivered IGF-1 to the CNS is still unclear. As critiqued by Howe (2009), the 
standard subcutaneous IGF-1 delivery utilised in both studies is likely to be too low to be 
biologically relevant, either in circulation or the CNS and cerebrospinal fluid (CSF). It is 
therefore still too early to conclude that IGF-1 has no effect on ALS patients. Further 
complicating the matter, Lai et al. (1997) (placebo (n = 90) vs rhIGF-I 0.1 mg/kg/day (n = 
87)) observed that the progression of functional impairments to ALS patients receiving 0.10 
mg/kg/day subcutaneous rhIGF-I injections were 26% slower than in patients receiving 
placebo, accompanied by a significant extension to survival. These contradicting results 
suggest further research is required to understand the role of IGF-1 in ALS. 
  
In summary, our current understanding of the role of GH/IGF-1 in ALS is limited. 
While current literature suggests that GH and IGF-1 promote growth and repair of neurons, 
clinical attempts to treat ALS patients with these growth factors have yet to yield beneficial 
results. Further understanding of the roles GH/IGF-1 play in ALS may reveal insights into 
potential targets for therapy.  
 
1.3 Hypothesis and aims 
Amyotrophic later sclerosis (ALS) is a degenerative disease of motor neurons and skeletal 
muscles. Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) are reduced in 
ALS patients and animals at the latter stages of disease. GH and IGF-1 play critical roles 
in growth, development, and repair of the skeletal muscle and nervous systems. There 
have yet to be ALS studies documenting the progressive changes to pulsatile GH 
secretion relative to disease progression. Thus, this thesis aims to characterise the release 
of GH/IGF-1 in a pre-clinical mouse model of ALS, relative to disease onset and 
progression. It was hypothesised that GH/IGF-1 signalling is critical in delaying disease 
progression in ALS, and that GH deficiency is associated with poor prognosis. This 
hypothesis was addressed by the following aims: 
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Aim 1: To confirm that the hSOD1G93A mouse is a suitable model to study the role of 
growth hormone in ALS. 
Aim 1 rationale:  
Past studies have revealed GH deficiency in ALS patients. Understanding the underlying 
pathology may further our understanding of ALS, leading to better diagnostics and 
treatments. In order to study this phenomenon in the hSOD1G93A (SOD) mouse model, we 
must first determine whether GH deficiency observed in ALS patients is conserved in SOD 
mice during the symptomatic stage(s) of disease.  
Aim 2: To investigate whether the role of GH and its release relates to disease progression 
in the hSOD1G93A mouse model of ALS. 
Aim 2 rationale: 
There is currently no empirical data detailing the release of GH in ALS patients or animal 
models throughout disease progression. Understanding the relationship between GH/IGF-
1 release and signalling with disease symptoms may expose novel pathological processes 
that could be manipulated for therapy. Intervention by altering growth factors in ALS mice 
models at different stages of disease have yielded varying degrees of efficacy, suggesting 
their roles may not be uniform throughout disease progression. Better understanding of 
when and how GH/IGF-1 alterations occurs may lead to more effective utilisation of 
GH/IGF-1 and other growth factors in the treatment of ALS. 
To address aims 1 & 2, four experiments were formulated: 
Experiment 1: Determine the pulsatile GH secretion profile of the hSOD1G93A mouse 
model of ALS throughout disease progression. 
Experiment 2: Determine whether the hypothalamic control of GH secretion and 
GH-R expression in skeletal muscles of the hSOD1G93A mouse model of 
ALS reflect the release of GH at the onset stage of disease. 
Experiment 3: Determine whether there is a correlation between pulsatile GH 
secretion and the histopathological hallmarks of ALS in the hSOD1G93A 
mouse model of ALS at the onset stage of disease. 
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Experiment 4: Determine whether circulating and skeletal muscle-specific IGF-1, 
and IGF-1R expression in the hSOD1G93A mouse model of ALS reflect 
the changes to GH release at the onset stage of disease. 
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2 Chapter 2: Methods – Part one 
2.1  Animals 
Male hSOD1G93A mice [B6.Cg-Tg(SOD1- G93A)1Gur/J] (SOD) were used as the animal 
model for ALS in this study. The SOD mouse carries a mutated copy of the human SOD1 
gene, containing a point substitution of a glycin (G) to an alanine (A) at position 93. SOD 
mice and their wild-type (WT) littermates were bred at the University of Queensland from 
founding stock imported from Jackson Laboratories (ME, USA). All animals were housed 
in a temperature-controlled room (22 ± 2 oC) maintained on a 12-hour light/dark cycle 
(lights on at 0630 hrs and off at 1830 hrs). Food and water was available ad libitum.  
All animals used for experiments were euthanised with sodium pentobarbital 
overdose (32.5 mg/kg; Virbac Animal Health, AUS; cat# 1PO643-1. All experiments and 
procedures are approved by the University of Queensland Animal Ethics Committee 
(Ethics Certificate: SBMS/093/09 NHMRC; SBMS/389/10 NHMRC; SBMS/092/12 
NHMRC; SBMS/562/12 NHMRC/MNDRIA; SBMS/563/12 NHMRC/MNDRIA; 
SBMS/555/12 NHMRC), and were performed in accordance to the Queensland 
Government Animal Care and Protection Act 2001, associated Animal Care and Protection 
Regulations (2002 and 2008), and the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes, 7th Edition (National Health and Medical Research 
Council, 2004). 
 
2.2 Classification of disease stages in the hSOD1G93A mouse model of ALS 
Animals were assessed at ages that corresponded to predefined stages of disease 
progression based on observable changes to motor function: pre-symptomatic (PS, 30-36 
days old): when no ALS-like symptoms are observed; disease onset (OS, 63-75 days old): 
where a reduction in hind limb grip-strength is first observed (Lee et al., 2013); mid-
disease (MD,110-130 days old): prior to severe symptoms; and end-stage (ES, 150-175 
days old): when animals reached pre-determined end-points reflecting severe motor 
impairments, including the loss of righting reflex, inability to feed or drink, or other 
debilitating symptoms such as infections. 
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2.3 Assessment and analysis of endocrine profile 
2.3.1 Pulsatile growth hormone secretion and pituitary growth hormone content 
2.3.1.1 Mouse whole blood collection for pulsatile GH secretion assessment 
Due to the pulsatile nature of GH secretion, one-off samplings which rely on the 
assumption that readings do not differ significantly over time is unreliable. Therefore in this 
study, I assessed GH levels of serial blood samples in the same animals to assess the 
pulsatile GH secretion over time. To achieve this, sequential blood samples were collected 
via a modified tail clip approach which was developed and optimised to minimise potential 
stress-induced disruptions to GH secretion, while allowing for high frequency sampling to 
assess pulsatility (Steyn et al., 2011). The mice were first held in a cardboard roll, leaving 
the tail exposed at one end. The distal ~0.5 mm of the tail was excised using a sterile 
surgical blade (ProsciTech, QLD, AUS). 2 µl of whole blood samples were collected into 
0.05% tween-20 in phosphate buffer saline (PBST, v/v) at 10 mins intervals for a period of 
6 hrs following transition into the light cycle (0700 to 1300 hrs; 36 time points). Samples 
were vortexed and frozen on dry ice immediately following collection.  
 
2.3.1.2 Mouse pituitary gland collection for GH content assessment 
To investigate the capacity for the mice to produce and release GH, this study examined 
the total GH content within the pituitary gland. The mouse pituitary gland is positioned at 
the base of the skull in a depression of the sphenoid bone, an anatomical structure known 
as the sella turcica (Tzou et al., 2010). To isolate the mouse pituitary gland, the brain was 
first extracted. To extract the brain, the scalp was first cut and lifted to reveal the skull. The 
cranium was then removed by careful dissection along the circumference. Removal of the 
cranium revealed the brain, which was then carefully extracted using blunted forceps or 
spatulas. Upon the removal of the brain, the pituitary gland (surrounded laterally by the 
trigeminal nerves and anteriorly by the optic chiasm (Tzou et al., 2010)) was then isolated 
from the surrounding dura mater. The pituitary gland was then collection into lysis buffer 
(50 mM Tris-HCl, 150 mM NaCl, 10 mM NaF, 10 mM Na4P2O4, 1 mM Na3VO4, 1% NP-40, 
and protease inhibitor (Roche, CHE; cat# 11836153001).  
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2.3.1.3 In-house GH sandwich enzyme-linked immunosorbent assay (ELISA) 
Assessment of whole blood and pituitary gland GH levels were determined using an in-
house sandwich ELISA (Steyn et al., 2011). 96-well plates (Corning Inc., USA) were 
coated with 50 µl of capture antibody (1:40 000; monkey anti-rat GH (rGH)-IC-1; NIDDK-
NHP; cat# AFP411S) and incubated overnight at 4 °C. Prior to sample loading, each well 
was incubated with blocking buffer (5% skim milk powder (SMP) in 0.05% PBST) for 2 hrs 
at room temperature (RT) to reduce non-specific binding. A 9-point standard curve was 
then generated using a mouse GH (mGH) reference preparation (National Institute of 
Diabetes & Digestive & Kidney Diseases; NIDDK-NHP, MD, USA; cat# AFP-10783B,) by 
two-fold serial dilution (8 ng/ml to 0.03 ng/ml) in PBST (pH 7.4) supplemented with 0.2% 
bovine serum albumin (BSA-PBST). Standards, samples and quality controls (50 µl) were 
loaded into the pre-coated plate and incubated for 2 hrs at RT. Wells were then washed 
and replaced with 50 µl of detection antibody (1:40 000; rabbit antiserum to rat GH, 
NIDDK-NHP, MD, USA; cat# AFP5672099) and incubated for 1.5 hrs at RT. Following 
washing, the plates were incubated with 50 µl of horseradish peroxidise (HRP)-conjugated 
anti-rabbit IgG (1:2000; GE Healthcare, UK; cat# NA934) for 1.5 hrs at RT. Finally, 100 µl 
of O-phenylenediamine (OPD; Invitrogen, CA, USA; cat# 002003) substrate was added to 
generate an enzymatic colorimetric reaction. The reaction was stopped by the addition of 
3M hydrochloric acid. Between each of the steps, the plates were washed three times for 3 
mins with PBST. The absorbance of each well was read on a TECAN Sunrise 96 
monochromatic microplate reader (TECAN, SUI) at a wavelength of 490 nm (reference 
wavelength: 650 nm). The concentration of GH in each well was calculated against a non-
linear regression of the standard curve. Pituitary release of GH was estimated from whole 
blood samples via a deconvolution analysis (Steyn et al., 2011, Liu et al., 2009, Steyn et 
al., 2012), which identified i) the number of pulses; ii) total GH secretion; iii) total GH 
secretion rate per pulse; iv) mean peak secretion rate of total pulses  (mass per pulse, 
MPP); v) basal secretion rate; vi) mode of secretion (i.e. time to peak); and vii) 
approximate entropy (ApEN): regularity of the pulses as a function of probability. ApEN of 
pulsatile GH secretion were considered regular when the P value was at 0.35 or below, 
and progressively less regular as the P value approached 1. Pituitary gland GH levels 
were normalised to total protein (determined by bicinchoninic acid (BCA) protein assay 
(ThermoFisher Scientific, USA; cat# 23225). 
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2.3.2 Plasma and tissue lysate preparation 
Following sacrifice, terminal blood samples were collected from the mice via cardiac 
puncture. The blood was then transferred into EDTA-precoated tubes (SARSTEDT, DEU; 
cat# 41.1395.005) and centrifuged for 3 mins. The separated plasma was then stored at -
20 oC until needed. To determine tissue-specific substrate levels, protein extractions from 
skeletal muscle, liver, pituitary gland, or fat were prepared under the same conditions 
unless otherwise specified. Tissues/organs were initially snap-frozen on dry ice 
immediately after excision. While still frozen, the tissues were individually reduced to 
powder with a mortar and pestle kept on dry ice to maintain the frozen state of the tissue. 
The samples were then lysed in lysis buffer containing 10 mM EDTA, 50 mM HEPES, 150 
mM NaCl, 30 mM NaF, 10 mM Na4P2O7, 1 mM Na3VO4, 1% Triton-X, and protease 
inhibitors (Roche, CHE; cat# 11836153001). The homogenates were vortexed for 60 secs 
before being left on ice for 60 mins to allow for complete lysis of the tissue and optimise 
protein yield. Samples were centrifuged at 13,000 rmp for 30 mins at 4 oC. The 
supernatants were kept and stored at -80 oC until needed. 
 
2.3.3 Circulating and muscle-specific insulin-like growth factor-1 
Circulating and muscle-specific IGF-1 (mIGF-1) levels were determined using a 
commercial mouse/rat IGF-1 ELISA (R&D Systems, USA; cat# MG100). Plasma and 
gastrocnemius muscle lysates were first prepared as mentioned previously (section 2.3.2), 
and diluted with Calibrator Diluent RD5-38 (R&D Systems, USA; cat# 895555) to pre-
optimised loads: muscle protein lysate ~1-4 mg/ml, plasma 1:600. Prior to sample loading, 
an 8-point standard curve was first generated using mouse/rat IGF-1 standard (R&D 
Systems, USA; cat# 892745) by two-fold serial dilution (2,000 pg/ml – 31.2 pg/ml, plus 
blank) using Calibrator Diluent RD5-38. 50 µl of each standard, sample, and quality control 
(R&D Systems, USA; cat# 892746) were then loaded, topped with an additional 50 µl of 
Calibrator Diluent RD5-38 to all wells of the 96-well microplate (R&D Systems, USA; cat# 
892743). The plates were then incubated at RT for 2 hrs. All wells were then decanted and 
washed with wash buffer (R&D Systems, USA; cat# 895003) before 100 µl mouse/rat 
Conjugate (R&D Systems, USA; cat# 892744) was added per well. The plates were then 
incubated for another 2 hrs at RT. Following a wash, 100 µl of the Substrate solution 
(equal parts colour reagent A and colour reagent B; R&D Systems, USA; cat# 895000 & 
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895001) was added to each well, then incubated for 30 mins at RT. At the end of the 
incubation, 100 µl of Stop solution was added to each well to halt the reaction between the 
conjugate enzymes (bound to IGF-1) and the substrate. Between each of the steps, the 
plates were washed five times with wash buffer (R&D Systems, USA; cat# 895003). 
Finally, the plates were read at a wavelength of 450 nm (reference wavelength: 540 nm) 
within 30 mins after the end of the assay on a TECAN Sunrise 96 monochromatic 
microplate reader (TECAN, SUI). The IGF-1 concentration of each sample was determined 
via a four-parameter logistic curve fit of the standard curve. mIGF-1 levels were 
normalised to total protein (determined by bicinchoninic acid (BCA) protein assay 
(ThermoFisher Scientific, USA; cat# 23225). 
 
2.4 Assessment of receptor protein expression in skeletal muscles 
In order to determine whether the capacity of skeletal muscles to respond to GH and IGF-1 
is altered in ALS mice, this study investigated the changes to protein expression of GH-R 
and IGF-1R in SOD mice via western blotting. Mouse gastrocnemius muscle lysates were 
first prepared as mentioned previously (sect. 2.3.2). Samples were then resolved by SDS-
PAGE and transferred to nitrocellulose membranes. Membranes used to detect IGF-I 
receptor α subunits (IGF-IRα) and IGF-I receptor β subunits (IGF-IRβ) were blocked in 5% 
skim milk/0.1% Tris-buffered saline with Tween-20 (TBS-T). Membranes for GH-R were 
blocked in 2.5% BSA/TBS-T. Membranes were incubated overnight with anti-IGF-IRα 
(1:150; Santa-Cruz, USA; cat# sc-712;), anti-IGFIRβ (1:100; Santa-Cruz, USA; cat# sc-
713), or anti-GH-R (1:1 000; Sigma-Aldrich, USA; cat# G8919;) and detected with donkey 
anti-rabbit IgG HRP (1:10 000; Amersham plc, UK; cat# NA934) or rabbit anti-goat IgG 
HRP (1:20 000; Invitrogen, USA; cat# 81-1620;). Blots were then stripped and reprobed 
with anti- glyceraldehyde 3-phosphate dehydrogenase (GAPDH)(1:15 000; Merck 
Millipore, USA; cat# MAB374;) and detected with sheep anti-mouse IgG HRP (1:10 000; 
Amersham plc, UK; cat# NA931) to verify equal loading of protein. Densitometric analyses 
of immuno-reactive bands were carried out using ImageJ software to determine final 
protein expression. The integrated pixel value of each protein band was determined by 
multiplying the intensity value by its area value. The integrated pixel value for each protein 
band was then normalised to its corresponding GAPDH band to account for variable 
protein loading.  
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2.5 Assessment of gene expression of hypothalamic regulators of GH secretion and 
muscle GH receptors 
To investigate whether the central control of GH release is altered in ALS, quantitative 
polymerase chain reaction (PCR) was used to determine the mRNA expression of the two 
dominant signals that control GH release from the hypothalamus: Srif and Ghrh. This first 
required to extraction of the brains and isolating the ARC and PevN, which contains large 
distributions of GHRH and SRIF neurons (Mano-Otagiri et al., 2006, Tannenbaum et al., 
1998, Ohtsuka et al., 1983, Minami et al., 1998). The brain – containing the hypothalamus, 
was first extracted as previously described (sect. 2.3.1.2). Brain tissue biopsies containing 
the ARC and PevN were collected using a modified micropunch technique for each animal 
(Palkovits, 1973). In addition, the capacity of skeletal muscles to response to GH was also 
investigated by determining GH-R mRNA and protein expression in the mouse 
gastrocnemius muscles. To determine Gh-r mRNA levels, the whole mouse gastrocnemius 
muscles were prepared by first snap freezing on dry ice immediately following extraction. 
While still on dry ice, each muscle was ground in a mortar and pestle separately into fine 
powder. Following collection, both hypothalamic and skeletal muscle samples were 
suspended in 1 ml of TRIzol (Invitrogen, USA; cat# 15596-026) to dissociate the tissue for 
RNA extraction. RNA was isolated using the Invitrogen TRIzol Plus RNA Purification Kit 
(Invitrogen, USA; cat# 12183-555). Lysates were incubated with TRIzol at RT for 5 
minutes to allow complete dissociation of nucleoprotein complexes. 200 µl of chloroform 
was then added to each 1 ml lysate, and was shaken vigorously by hand for 15 secs. After 
incubation at RT for 3 mins, samples were centrifuged at 12,000 x g at 4 C for 15 mins; or 
until the mixture was separated into three distinct layers: a lower red phenol-chloroform 
phase, a white interphase, and a colourless upper aqueous phase containing RNA. The 
upper aqueous phases were then transferred to fresh tubes. Equal volumes of 70% 
ethanol was then added to each sample and mixed well by vortexing. Samples were 
transferred to RNA spin cartridges and centrifuged at 12,000 x g at RT for 15 secs to 
isolate the RNA from the mixture. 700 µl of wash buffer I was added to each RNA spin 
cartridge and centrifuged at 12,000 x g at RT for 15 secs. This was followed by the 
addition of 500 µl of wash buffer II centrifuged at 12,000 x g at RT for 15 secs. An addition 
1 min centrifugation at RT was conducted for each tube to remove any remaining buffer. 
All spin cartridge flow through were discarded between all steps. Washing steps using 
wash buffer I and wash buffer II were then repeated once to ensure sample purity. 
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Following sample washing, RNA Spin cartridges were transferred into clean RNA recovery 
tubes, followed by the addition of 30 μl RNase-free water to the center of the RNA Spin 
Cartridge membrane. Samples were then allowed to incubate at RT for 1 min to maximize 
RNA recovery. Each sample was then centrifuged at ≥12,000 x g at RT for 2 mins twice 
using the same 30 μl of RNase-free water to maximize RNA yield. Total RNA 
concentration in each sample was quantified using a NanoDrop spectrophotometer 
(Thermo Scientific, USA; cat# ND-1000). RNA were transcribed into cDNA using a 
SuperScript VILO cDNA synthesis kit (Invitrogen, USA; cat# 11754-050) using 70 ng of 
total RNA per reaction. Each 70 ng/20 µl RNA sample was coupled to 4 μl of 5x VILO 
reaction mix, and incubated at 25 °C for 10 mins, 42 °C for 60 mins, and finally 85 °C for 5 
minutes before being cooled on ice. Commercially available gene-specific custom TaqMan 
Gene Expression Assays (Life Technologies, USA; Cat. # 4331182) were used to amplify 
Ghrh, Srif, and Gh-r mRNA expression from the previously described cDNA products. All 
reactions were formatted across Fast 96-well MicroAmp plates (Applied Biosystems, USA; 
cat# 4346907) in 20 µl reactions. The StepOne Plus system (Applied Biosystems, USA) 
was used to detect fluorescence during each cycle and data was displayed as an 
amplification plot, where results were normalised to GAPDH. Final measures are 
presented as relative levels of corrected gene expression compared to age-matched WT 
controls based on the ΔΔCT analysis method. 
 
2.6 Assessment of the histopathological hallmarks of ALS 
To understand the relationship between GH/IGF-1 and ALS pathology in ALS mice, I first 
needed to establish quantifiable standardised hallmarks. To this end, I focused on the 
histopathological changes in lower motor neuron (LMN) counts and neuromuscular 
junction (NMJ) innervation. The limb-onset motor impairments exhibited in the SOD mouse 
model of ALS is most prominent in the hind limbs, thus the focus of this study was on the 
motor neurons of the lumbar spinal cord (which innervate the hind limbs) and the 
gastrocnemius muscles. 
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2.6.1 Assessment of motor neuron counts 
Quantification of motor neuron number was conducted via histology. The thorax of the 
mice were opened and transcardially flushed with 2% sodium nitrite in phosphate buffer 
(PB, pH 7.4). To remove the spinal cord, the vertebrae were transected at the brachial and 
sacral levels. The vertebral cavities were then flushed with 2% sodium nitrite in PB with a 
blunted 23-gauge needle. Spinal cords were post-fixed for 2 hrs at 4 °C in 4% 
paraformaldehyde (PFA, Sigma-Aldrich, USA; cat# P6148) in PB (PFA/PB, pH 7.3). Spinal 
cords were washed three times for 5 mins each in phosphate buffered saline (PBS, pH 
7.4) to remove PFA prior to graded sucrose dehydration (15% at 4 °C overnight, then 30% 
at 4 °C overnight). Spinal cords were then transected at the rostral lumbar level, and the 
lumbar spinal cords were mounted in optimal cutting temperature cryoprotectant (OCT; 
Sakura, JPN; cat# 4583). Serial transverse cryosections (16 µm) of the lumbar spinal cord 
were cut at −17 °C on a Leica CM1850 UV cryostat (Leica, HE, DEU), and collected on 
Superfrost plus slides (Menzel-Glaser, DEU), and stored at −20 °C. Sections were stained 
with 0.1% thionin solution in acetate buffer (pH 3.9) to identify motor neurons in the lumbar 
spinal cord. Spinal cords were imaged using an Olympus BX51 microscope (Olympus 
America Inc., USA) with a x10 and x20 UPlan Fl objective (numerical aperture (NA) = 0.3 
and 0.5, respectively). Motor neurons were visualised and quantified at x40 magnification 
via bilateral counts of total visible motor neurons in the complete lateral motor column 
(lamina 9) from L2-L6, unless otherwise specified. Motor neurons were quantified in every 
fifth section to minimize co-efficient of error associated with motor neuron counting 
(Slomianka and West, 2005). Motor neurons counted were required to have a large, darkly 
stained cell body, a pale nucleus with a continuous boundary, and one or more darkly 
stained nucleoli (Fig. 7)(Banks et al., 2005). 
 
Figure 7. Thionin stained motor neurons. Example of healthy motor neuron 
(arrow)  with a large, darkly stained cell body, a pale nucleus with a continuous 
boundary, and a darkly stained nucleoli (reproduced from Banks et al., 2005). 
 
56 
 
2.6.2 Assessment of neuromuscular junction innervation 
Quantification of NMJ innervation was conducted via whole-mount immunofluorescence of 
the gastrocnemius muscles. The gastrocnemius muscles were first dissected free and 
post-fixed at RT for 20 mins in PFA/PB. Muscles were then washed three times for 
10 mins with 0.1% glycine in PBS to remove PFA. Muscle fibres were then teased out from 
the muscle and suspended in PBS. To detect acetylcholine receptors plaques at the motor 
end-plate, muscle fibres were incubated in Alexa 555-α-bungarotoxin (1:500; α-BTX, 
Invitrogen, USA; cat# B3545) in block solution (2%BSA/0.2% triton X 100 in PBS) for 30 
min at RT. The muscle fibres were then washed once with PBS prior to incubation in -20 
oC methanol for 5 mins to fix the α-BTX. The muscle fibres were washed with PBS and 
incubated with a cocktail of anti-synaptophysin (1:50; Invitrogen, USA; cat# 180130) and 
anti-neurofilament (1:500; Sigma-Aldrich, USA; cat# N4142) antibodies in block solution at 
4 °C for 3 days, to detect the presynaptic nerve terminal and axonal branches respectively. 
Anti-synaptophysin and anti-neurofilament antibodies were detected with Alexa-488 goat 
anti-rabbit secondary antibody (1:250; Invitrogen, USA; cat# A21206) in block solution for 
1 hr at RT. The muscle fibres were then mounted onto Superfrost slides (Menzel-Glaser, 
DEU). To assess innervation status, acetylcholine receptor-end-plate plaques of the NMJs 
were viewed under a Zeiss LSM Meta 510 upright confocal microscope using a Plan-
Apochromat x20 air objective (NA = 0.8; Carl Zeiss, DEU). NMJs were then scored over 20 
random fields for each animal. End-plates were classed as either being innervated (co-
localised with synaptophysin and neurofilament; Fig. 8, A & B) or non-innervated (absence 
of co-localisation with synaptophysin and neurofilament; Fig. 8C). Final results were 
expressed as percent innervation (innervated NMJ/total end plate number). 
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Figure 8. Neuromuscular junctions of various degrees of innervation. The motor 
end-plates are represented by acetylcholine receptors plaques (red); presynaptic 
terminals are represented by synaptophysin and neurofilament (green). 
Neuromuscular junctions were classed as completely innervated (A), partially 
innervated (B), and non-innervated (C). Scale bar = 20 um (reproduced from Ngo et 
al., 2012). 
 
2.7 Statistical analyses 
Prior to statistical analysis, NMJ percent innervation was first expressed through an 
arcsine transformation (arcsin(x)) to stabilise variance for analysis. Results of the separate 
disease stages (PS, OS, MD, and ES) between the SOD and WT control groups were 
analysed in GraphPad Prism v6.07 using two-tailed unpaired t tests. Nonparametric 
Spearman correlation was also employed to determine the correlation between pulsatile 
GH secretion and the histopathological hallmarks of ALS in the SOD mouse model, 
whereby a Bonferroni correction was calculated based on α = 0.05; a P value of ≤ 0.05 
was accepted as significant in all other reported results. All results were presented as 
mean ± SEM unless otherwise specified. 
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3 Chapter 3: Results – Part one  
3.1 Experiment 1: The pulsatile GH secretion profile of the hSOD1G93A mouse model of 
ALS throughout disease progression. 
While the hSOD1G93A (SOD) mouse model of ALS is accepted as a suitable model for ALS 
symptoms, it is unclear as to whether the changes in GH and IGF-1 also accurately reflect 
what is seen in patients. Mapping the pulsatile GH secretion profile at the latter stage of 
disease in the SOD mouse model, where previous studies in patients display GH 
deficiency (Morselli et al., 2006), would provide the best indication of the accuracy of this 
model for assessing the GH/IGF-1 axis in ALS. In conjunction with this goal, simultaneous 
mapping of the pulsatile GH secretion profile throughout the earlier stages of disease 
would also reveal the relationship between GH secretion and disease progression of ALS. 
Results would further define the role of GH in ALS, and potentially reveal novel links that 
can be utilised in therapy. I hypothesised that GH secretion would be significantly reduced 
at the end-stage of disease in the SOD mice, signifying that it is suitable in reflecting the 
changes to GH relative to ALS patients. I also hypothesised that there would be a 
persistent reduction of GH secretion from the onset stage through to the end-stage of 
disease. 
 
3.1.1 Growth hormone secretion changes drastically throughout disease progression in 
hSOD1G93A mice. 
Pulsatile GH secretion was assessed in SOD mice over four age groups corresponding to 
pre-symptomatic (PS), onset (OS), mid-disease (MD), and end-stage (ES); and were 
compared to age-matched wild-type (WT) controls. Results revealed that there was a 
significant decline in pulsatile GH secretion in SOD mice at ages corresponding to the ES 
stage of disease (fig. 9D; table1). This result gave sufficient evidence that the SOD mouse 
made for an appropriate model to investigate the role of GH in ALS, meeting the criteria 
needed to address aim 1. To address aim 2, I first mapped the pulsatile GH secretion 
profiles of SOD mice at earlier stages of disease (PS, OS, MD) to investigate changes 
prior to disease end-stage. Results revealed no significant changes to GH secretion at the 
PS stage of disease relative to age-matched WT controls. Both SOD mice and their age-
matched WT counterparts exhibited frequent, erratic, high amplitude pulses characteristic 
of animals during pubertal development (fig. 9A). In contrast, as the animals progressed 
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into the OS stage of disease, age-matched WT controls experienced an age-associated 
decline in pulsatile GH secretion, whereas the SOD mice maintained secretion levels 
compared to PS (fig. 9B; table 1). Interestingly, both SOD mice and WT controls also 
experienced significant declines in pulse frequency as they reach ages corresponding the 
OS stage of disease, likely reflecting the maturation of pulsatility (fig. 9B; table 1). As 
animals reached the MD stage of disease (half way between the OS and ES stages of 
disease), GH pulses of SOD mice are returned to comparable levels to age-matched WT 
controls, but maintained a significantly elevated basal GH secretion (fig. 9C; table 1). 
Taken together, my results demonstrated that GH secretion was unaltered at the PS stage 
of disease, supporting my initial hypothesis. Previously unforeseen was that GH secretion 
was relatively greater in SOD mice compared to age-matched WT controls. Closer 
examination revealed that this appears to be a maintenance of the high GH secretion 
characterised by mice at ages corresponding to the PS stage of disease, rather than a 
sudden increase in GH secretion. This maintenance of GH secretion is contrasted in WT 
control mice, which exhibit reduced GH secretion levels upon reaching ages 
corresponding to the OS stage of disease. This reduction in GH secretion coincides with 
the end of the pubertal growth spurt of the mice (~10 wks of age), where growth rate is 
significantly reduced thereafter (fig. 10). However, this maintenance of high GH secretion 
does not significantly increase linear growth in the SOD mice compared to age-matched 
WT controls (fig. 10), suggesting this may be an acute increase in GH secretion which 
eventually declines, as evident in the MD and finally ES stages of disease (fig. 9, C & D; 
table 1). 
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Figure 9. Altered pulsatile growth hormone secretion in hSOD1G93A mice 
throughout disease progression. Pulsatile growth hormone (GH) secretion in 
hSOD1G93A mice (SOD, shaded circles) and age-matched wild-type (WT) controls 
(open circles) at ages corresponding to the presymptomatic (A) onset (B), mid-
disease (C), and end-stage (D) stages of disease progression. Graphs illustrate 
representative examples from a single animal (left column) and resulting output 
figures demonstrating GH secretion rate (right column). Samples were collected for 6 
hours at 10-minute intervals starting from 0700 hrs (30 mins after the initiation of the 
light cycle). A regular periodicity of pulsatile GH secretion was characterised by peak 
secretion periods dispersed between stable low baseline secretion periods. Pulsatile 
GH secretion in SOD mice remained unchanged prior to disease onset (A), was 
elevated at disease onset (B), returned to normal at mid-disease (C) and was 
reduced at disease end-stage (D) (data summarized in Table 1). The onset of pulses, 
as identified by deconvolution analysis, is illustrated along the x-axis of the output 
figures (black arrows). 
 
Table 1: Deconvoluted parameters of pulsatile growth hormone secretion in 
hSODG93A mice throughout disease progression. Deconvolution analysis 
parameters of pulsatile growth hormone (GH) secretion from hSODG93A (SOD) mice 
and age-matched wild-type (WT) controls at ages prior to the development of 
hindlimb weakness (Pre-symptomatic), at ages corresponding to the appearance of 
hindlimb weakness (Onset), at ages corresponding to moderate hindlimb weakness 
(mid-disease), and at ages corresponding to severe hindlimb weakness and overall 
motor impairments (End-stage). 
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For GH, samples were collected at 10-minute intervals between 0700 hrs and 1300 hrs. Data are 
presented as mean ± SEM, *P ≤ 0.05 was considered significant. 
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Figure 10. Linear growth of hSOD1G93A mice throughout life. Body length of 
hSOD1G93A (SOD) mice throughout life was unaltered compared to age-matched 
wild-type (WT) control mice. Animals experienced significant growth between 6 to 10 
weeks of age, characteristic of pubertal growth. This is contrasted by a significant 
reduction in adult growth from 11 weeks of age onwards. Values are expressed as 
mean body length per age. A value of P ≤ 0.05 was accepted as significant; n = 15-
20/group. 
 
3.2 Experiment 2: The hypothalamic control of GH secretion, pituitary GH content, and 
GH-R expression in skeletal muscles of the hSOD1G93A mouse model of ALS at the 
onset stage of disease. 
To further address aim 2 (understand how GH and its release relates to disease 
progression in the SOD mouse), further investigations were undertaken to understand the 
hypothalamic control and pituitary gland content of GH, as well at the expression of GH-Rs 
on skeletal muscle. The understanding of basic hypothalamic signals regulating GH 
secretion – GHRH and SRIF – and GH synthesis in the pituitary gland provides the basic 
information needed to characterise the complex signalling pathways regulating GH 
release. Results from this experiment then provided the framework necessary for 
subsequent experiments outlined in this thesis. Furthermore, a focus was placed upon 
uncovering the relationship between GH and skeletal muscles, as the loss of skeletal 
muscle function – thus mobility and respiratory function – is a primary concern for ALS 
patients. Based on the findings of experiment 1, it was clear that the initial assumption that 
ALS is characterised only by GH deficiency was incorrect. More striking was that GH 
secretion significantly increased at the OS stage of disease compared to age-matched WT 
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controls (fig. 9; table 1), an unforeseen result which has never been reported in any prior 
studies. Efforts were therefore placed into understanding this phenomenon, which may 
help us better understand the role of GH in regards to ALS disease progression. Based on 
the findings of experiment 1, I hypothesised that SRIF expression in the hypothalamus 
would decrease, while GHRH would increase. In addition, pituitary GH content was also 
hypothesised to increase. Finally, I hypothesised that GH-R expression in skeletal muscles 
would not be affected. 
 
3.2.1 Increased growth hormone secretion in hSOD1G93A mice at the onset stage of 
disease was not due to altered hypothalamic signalling.  
The significantly greater release of GH into circulation in SOD mice at the OS stage of 
disease compared to age-matched WT controls (fig. 9; table 1) was not reflected in the Srif 
and Ghrh mRNA expression in the hypothalamus (fig. 11, A & B). SOD mice Srif mRNA 
expression was unchanged relative to age-matched WT controls (fig. 11A), while Ghrh 
mRNA expression was significantly reduced (fig. 11B). These results together suggested a 
suppression of GH release signals. The increase in GH release may therefore be due to 
direct stimulation of the pituitary gland to synthesise and release GH. However, although 
pituitary GH content reflected GH secretion by being significantly reduced at the ES stage 
of disease (fig. 11C), and unchanged at the PS stage of disease in SOD compared to age-
matched WT controls (fig. 11C), there was no significant difference in pituitary GH content 
between SOD and WT controls at the OS stage of disease (fig. 11C). Taken together, 
none of my results showed any evidence that the hypothalamic control of GH secretion or 
pitutary GH production contribute to the increased GH secretion in SOD mice at the OS 
stage of disease.  
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Figure 11. Reduced central growth hormone release signalling and pituitary 
gland content in hSOD1G93A mice. Hypothalamic somatostatin (Srif) (A) and growth 
hormone-releasing hormone (Ghrh) (B) mRNA expression in hSOD1G93A (SOD) mice 
at the onset (OS) stage of disease relative to age-matched wild-type (WT) controls; 
and pituitary growth hormone (GH) content (C) in WT and SOD mice at ages 
corresponding to the presymptomatic (PS), onset (OS), and end-stage (ES) ages of 
disease progression. No change in the expression of hypothalamic Srif mRNA was 
observed, whereas Ghrh mRNA expression declined significantly relative to age-
matched WT controls. Pituitary growth hormone (GH) content remained unchanged 
at disease onset, then declined significantly toward the ES stage of disease 
progression. Values are expressed as mean ± SEM. A value of P ≤ 0.05 was 
accepted as significant; n = 6/group. 
 
3.2.2 Increased growth hormone secretion in hSOD1G93A at the onset stage of disease 
was not due to altered growth hormone receptor expression.  
While an increase in the pro-release signals of GH from the hypothalamus may result in 
the increase of GH secreted into circulation, reduced suppressive systemic feedback 
signals may also lead to increased GH secretion. As such, GH-R expression in skeletal 
muscle was assessed in SOD and age-matched WT mice to determine whether the 
potential capacity for skeletal muscles to respond to GH had changed, and whether this 
may contribute to the increased secretion of GH at the OS stage of disease in SOD mice. I 
determined the Gh-r mRNA and GH-R protein expression in the gastrocnemius muscles of 
SOD mice at the PS, OS, and ES stages of disease (fig. 12). When compared with age-
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matched WT controls, there were no significant changes in protein (fig. 12, A & B) or 
mRNA (fig. 12C) expression of GH-R in SOD mice throughout disease. My results 
suggested that, despite altered pulsatile GH secretion profiles at both the OS and ES 
stages of disease, the potential capacity for GH to act on skeletal muscle in SOD mice 
may not be altered. 
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Figure 12. Muscle-specific growth hormone receptor expression is unaltered in 
hSOD1G93A mice.  Growth hormone receptor (GH-R) protein (A & B) and gene 
expression (C) in hSOD1G93A (SOD) mice and age-matched wild-type (WT) controls 
at ages corresponding to the pre-symptomatic (PS), onset (OS), and end-stage (ES) 
stages of disease. No change in the expression of muscle GH-R was observed in 
SOD mice throughout disease progression. For western blot protein expression, 
assessment was limited to the band corresponding to 71 kDa (A), and was 
normalised to the GAPDH band. The lack of change in GH-R expression was 
confirmed by quantitative PCR for Gh-r mRNA (C). Values are expressed as mean ± 
SEM. A value of P ≤ 0.05 was accepted as significant; n = 6/group. 
 
3.3 Experiment 3: The relationship between GH and the histopathological hallmarks of 
ALS in the hSOD1G93A mouse model of ALS at the onset stage of disease. 
My previous finding that pulsatile GH secretion increased at the OS stage of disease in 
SOD mice suggested that it was related to the onset of hindlimb weakness of the ALS 
model. This implies that the increase in GH secretion may either have detrimental effects – 
potentially underlie/contribute to the onset of hindlimb weakness – or that it may be a 
response to the onset of hindlimb weakness as a protective mechanism. To investigate 
how this increase in GH secretion relates to the onset of hindlimb weakness – thereby 
further addressing aim 2 – I characterised the histopathological hallmarks of ALS – motor 
neuron degeneration and skeletal muscle innervation – at the OS stage of disease. 
Correlations were then drawn between the parameters of pulsatile GH secretion and the 
histopathological features of ALS, as a means to delineate whether GH plays a beneficial 
or detrimental role in ALS. As GH acts as an anabolic hormone, I hypothesised that GH 
was secreted in response to the onset of hindlimb weakness as a protective mechanism, 
and thus imposes a beneficial impact on neuromuscular innervation. I therefore 
hypothesised that the OS stage of disease in SOD mice would be characterised by 
significant losses of both motor neurons and skeletal muscle innervation when compared 
to age-matched WT controls. I also hypothesised that the degree of motor neuron and 
skeletal muscle innervation loss would be inversely proportional to GH secretion, 
suggesting that the increase in GH secretion is protective against the development of 
muscle weakness in ALS.  
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3.3.1 Onset of hindlimb weakness in hSOD1G93A mice was characterised by significant 
loss of neuromuscular junction innervation. 
I assessed the histopathological hallmarks of ALS in the SOD mice at the PS and OS 
stages of disease, along with age-matched WT controls. At the PS stage of disease there 
is no significant loss of NMJ innervation relative to age-matched WT controls (Fig. 13, D-
F). In conjunction to NMJ innervation, I also investigated the number of motor neurons in 
the spinal cord, specifically those innervating the crural flexors – muscles which contribute 
to flexion within the leg (fig. 14) – including the gastrocnemius muscle. Interestingly, there 
was a significant loss of crural flexor motor neurons in the SOD mice relative to age-
matched WT controls even at the PS stage of disease (fig.13, A-C). The loss of motor 
neurons in the SOD mice was further progressed at the OS stage of disease (fig.13, G-I). 
Taken together, these results illustrate that the loss of motor neurons precedes the loss of 
motor function, and the onset of hindlimb weakness is marked by the significant loss of 
NMJ innervation. 
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Figure 13. Onset of hindlimb weakness in hSOD1G93A mice characterised by 
significant loss of motor neurons and innervation. Histopathological assessment 
of disease progression in hSOD1G93A (SOD) mice by quantification of crural flexor 
motor neuron number (A-C & G-I) and neuromuscular junction (NMJ) innervation of 
the gastrocnemii (D-F & J-L) of SOD mice at ages prior to the development of overt 
symptoms (pre-symptomatic (PS), A-F), and the onset of hindlimb weakness (Onset 
(OS), G-L). Compared with age-matched wild-type (WT) controls, PS SOD mice had 
a modest yet significant reduction in the number of crural flexor motor neurons (A-C, 
black arrows), whereas NMJ innervation remained unchanged (D-F). At the OS stage 
of disease, SOD mice displayed a significant decrease in crural flexor motor neuron 
number (G-I, black arrows) and NMJ innervation (J-L, white arrows). NMJ innervation 
was assessed by the proportion of coexpression of AChR end-plates (red signal) with 
neurofilament (NF) and synaptophysin (SNP)-positive nerve axons and terminals 
(green signal). Insets of A, B, G, and H illustrate a magnified view of the spinal cord 
region of interest (area containing the crural flexor motor neuron pool). Scale bar (A, 
B, G, & H), 250 µm and 100 µm for insets. Scale bar (D, E, J, & K), 100 µm. Values 
are expressed as mean ± SEM. A value of P ≤ 0.05 was accepted as significant; n = 
5-6/group. 
 
 
 
 
Figure 14. Position of crural flexor motor neuron pools in the mouse spinal 
cord. Motor neurons innervating the crural (leg) flexors are positioned within L4-L5 
levels of the lateral motor column (lamina 9). 
 
3.3.2 There is a significant positive correlation between pulsatile growth hormone 
secretion and neuromuscular junction innervation, but not lumbar motor neuron 
numbers. 
Based on the previous observation that pulsatile GH secretion increased in SOD mice at 
the OS stage of disease (fig. 9; table 1) when loss of neuromuscular innervation was first 
evident (fig. 13), I hypothesised that increased GH secretion may be a response to the 
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loss of skeletal muscle innervation. To determine whether the increase in GH secretion is 
a response to the loss of motor neurons or skeletal muscle innervation, I assessed the 
relationship between pulsatile GH secretion and the spinal cord motor neuron number and 
skeletal muscle NMJ innervation. Matched measurements of pulsatile GH secretion 
profiles were correlated with the crural flexor motor neuron number in the spinal cord and 
the percentage NMJ innervation in the gastrocnemius of SOD mice at the OS stage of 
disease. In accordance with my previous observations, total, pulsatile, and MPP of GH 
secretion in SOD mice were elevated at the OS stage of disease compared to age-
matched WT controls (table 2). Similarly, when compared with age-matched WT controls, 
there was a significant decline in NMJ innervation and crural flexor motor neuron number. 
Analysis using Spearman correlation coefficient revealed that total, pulsatile, and basal GH 
secretion, and the MPP of GH secretion were positively correlated with the percentage of 
innervated NMJs in SOD mice (fig. 15, A-C; table 2). These results indicate that SOD mice 
with higher levels of GH secretion had higher innervation, suggesting that GH exerts a 
protective effect against the loss of innervation during the onset of hindlimb weakness. By 
contrast, crural flexor motor neuron number did not correlate with any of the parameters of 
pulsatile GH secretion (fig. 15, D-F; table 2), suggesting that the increase in GH secretion 
during the OS stage of disease is not a delayed response to the loss of motor neurons. All 
correlations are presented in table 2. 
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Figure 15. Correlation between pulsatile growth hormone secretion with the 
histopathological hallmarks of amyotrophic lateral sclerosis in hSOD1G93A mice 
at the onset stage of disease. Representative examples of total (A & D), pulsatile 
(B & E), and mean mass per pulse (MPP; C & F) of growth hormone (GH) secretion, 
correlated to the percentage of innervated neuromuscular junctions (% NMJ 
Innervation) in gastrocnemius muscles (A - C) and crural flexor motor neuron number 
(Motor Neuron Count) in L4 - L5 of the lateral motor column (D - F) of respective 
hSOD1G93A mice at the onset stage of disease. Spearman correlation analysis was 
performed to assess the relationship between parameters of pulsatile GH secretion 
following deconvolution analysis with percentage NMJ innervation and motor neuron 
count. Data for all parameters are summarised in table 2. For %NMJ innervation, n = 
16. For motor neuron count, n = 12. 
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Table 2. Deconvoluted parameters of pulsatile growth hormone secretion in 
hSODG93A mice at the onset of disease, and the status of the histopathological 
hallmarks of amyotrophic lateral sclerosis. Histopathological data (crural flexor 
motor neuron number and percentage neuromuscular junction (NMJ) innervation), 
deconvolution analysis parameters of pulsatile growth hormone (GH) secretion, and 
Spearman correlation analysis of deconvolution parameters of pulsatile GH secretion 
with percentage NMJ innervation of the gastrocnemius muscle, crural flexor motor 
neuron number from hSOD1G93A (SOD) and age-matched wild-type (WT) controls at 
ages corresponding to the onset of hindlimb weakness. 
 
For GH, samples were collected at 10-minute intervals between 0700 hrs and 1300 hrs. Data are presented as mean ± 
SEM, *P ≤ 0.05 was considered significant between comparisons of WT and SOD, whereas * P ≤ 0.008 was considered 
significant when correlating %NMJ innervation and motor neuron number with deconvoluted parameters of pulsatile GH 
secretion in SOD mice. 
 
3.4 Experiment 4: Circulating and skeletal muscle-specific IGF-1, and IGF-1R expression 
in the hSOD1G93A mouse model of ALS at the onset stage of disease. 
As IGF-1 mediates majority of the anabolic actions of GH, it was speculated that the 
benefits of GH in promoting/retaining NMJ innervation during the onset of hindlimb 
weakness (fig. 15; table 2) may be mediated by IGF-1. Circulating and muscle-specific 
IGF-1 (mIGF-1), along with IGF-1R expression in skeletal muscles, were therefore 
retrospectively determined in SOD mice to investigate whether GH may be acting through 
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IGF-1 to influence the onset of motor impairments observed in the ALS mouse model. 
Given my proposition that the beneficial effects of GH are mediated by mIGF-1, I 
hypothesised that both circulating and mIGF-1 levels would increase. As there was no 
anticipation that the capacity for skeletal muscles to response to IGF-1 would be altered, 
IGF-1R expression was hypothesised to remain unchanged. 
 
3.4.1 Increased growth hormone secretion in hSOD1G93A mice at the onset stage disease 
occurs alongside alterations in muscle-specific – but not circulating levels – of 
Insulin-like Growth factor-1. 
There was no significant difference in the expression of circulating IGF-I (fig. 16A), and 
mIGF-I (fig. 16B), IGF-IRα (fig. 16, C & D), and IGF-IRβ (fig. 16, E & F) protein in skeletal 
muscles of SOD mice at the PS stage of disease when compared with age-matched WT 
controls. Similarly, there were no significant changes in the expression of circulating IGF-I 
(fig. 16A), IGF-IRα (fig. 16, C & D), or IGF-IRβ (fig. 16, E & F) protein in the skeletal 
muscle of SOD mice at the OS stage of disease. However, the expression of mIGF-I 
protein in SOD mice was significantly higher at the OS stage of disease compared to age-
matched WT controls (fig. 16B). These results provided evidence to support the 
hypothesis that the increased GH secretion at the onset of hindlimb weakness acts 
through IGF-1 to support skeletal muscle innervation. 
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Figure 16. Increased insulin-like growth factor-1 levels in skeletal muscle of 
hSODG93A mice at disease onset. Circulating insulin-like growth factor-1 (IGF-I)(A), 
muscle-specific IGF-I (B), and muscle-specific IGF-1 receptor α subunit (IGF-IRα) (C 
& D) and IGF-1 receptor β subunit (IGF-IRβ) (E & F) expression in hSOD1G93A (SOD) 
mice and age-matched wild-type (WT) controls at ages corresponding to the pre-
symptomatic (PS) and onset (OS) stages of disease. No change in circulating IGF-I 
(A) or muscle-specific IGF-IRα and IGF-IRβ (C-F) expression was observed in PS or 
OS SOD mice. A significant increase in muscle-specific IGF-I in SOD mice at the OS 
stage of disease was observed (B). For IGF-IRα (C) and IGF-IRβ (E), the IGF-IR 
band was normalised to the GAPDH band. Values are expressed as mean ± SEM. A 
value of P ≤ 0.05 was accepted as significant; n = 6/group. 
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4 Chapter 4: Discussion – Part one 
The overarching goal of this thesis was to demonstrate the importance of GH and IGF-1 in 
ALS, and how further understanding of their roles may reveal insights into potential targets 
for therapy or biomarkers. It was hypothesised that GH/IGF-1 signalling is critical in 
delaying disease progression in ALS, and that GH deficiency is associated with poor 
prognosis. This hypothesis was formed on the basis that ALS is a degenerative disease of 
motor neurons and skeletal muscles, and that the anabolic effects of GH and IGF-1 
counteracted the loss of tissue. This was supported by previous evidence that GH 
secretion is reduced in ALS patients at the latter stages of disease (Morselli et al., 2006). 
To achieve these goals and address my hypothesis, two aims were initially developed: 1) 
to confirm that the hSOD1G93A mouse is a suitable model to study the role of growth 
hormone in ALS; and 2) to investigate whether GH and its release relates to disease 
progression in the SOD mouse model of ALS. 
 
4.1 Altered growth hormone secretion is associated with the onset of symptoms in 
hSOD1G93A mice. 
Aim 1 was to establish whether SOD mice made an acceptable model of the altered GH 
secretion seen in ALS patients. While SOD mice have long been used as an ALS animal 
model (Gurney et al., 1994), it does not necessarily mean that it presents with all the 
symptoms present in patients. As previous studies indicated that GH secretion is 
significantly reduced in ALS patients (Morselli et al., 2006), I sought to determine whether 
GH secretion was also impaired in the SOD mice. To this end, I observed significant 
reductions in the pulsatile secretion of GH at the ES stage of disease, where the SOD 
mice experience severe motor impairments. It was therefore concluded that the SOD 
mouse was an acceptable model of the altered GH secretion observed in ALS patients. 
This conclusion was made given that the reduction of GH levels was the only current 
criteria available regarding changes to GH (Morselli et al., 2006). Future studies will need 
to be made to further validate whether my observations in the SOD mice at earlier disease 
stages are also reflected in ALS patients. 
To address aim 2, I extended the assessment of pulsatile GH secretion to the earlier 
stages of disease in SOD mice. Given the degenerative nature of ALS, I hypothesised that 
the reduced level of the anabolic GH would already be evident following the OS stage of 
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disease. Contrary to my initial hypothesis, pulsatile GH secretion did not decline prior to 
disease end-stage (fig. 9; table 1). Remarkably, at the OS stage of disease – 
characterised by the onset of hindlimb weakness – pulsatile GH secretion was increased 
significantly (fig. 9; table 1). This novel observation that GH secretion increases in SOD 
mice suggests that the role of GH in ALS is dynamic, and changes over the course of 
disease progression. This temporal shift in GH secretion – and potentially actions – across 
different stages of disease may limit the affinity of GH/IGF-1-based interventions in ALS 
based on the time of intervention. This temporal change in the role of GH may suggest that 
delayed intervention has reduced effectiveness, and may explain the lack of therapeutic 
effect in ALS patients in previous studies (Sacca et al., 2012, Smith et al., 1993). 
 
4.2 Increased growth hormone secretion at the onset of hindlimb weakness is protective 
against the loss of skeletal muscle innervation in hSODG93A mice 
Having demonstrated that SOD mice experience a significant increase in pulsatile GH 
secretion at the onset of hindlimb weakness (fig. 9; table 1), I sought to determine whether 
this increase in GH secretion is protective against disease pathology. Given that GH is an 
anabolic hormone which drives cellular growth and repair, it is plausible that GH exerts a 
beneficial effect against neuromuscular degeneration in ALS. Furthermore, the overlapping 
of the onset of hindlimb weakness and the increase in GH secretion indicates a potential 
relationship between the two events. I demonstrated that even at the PS stage of disease 
– prior to the onset of hindlimb weakness – SOD mice already exhibited significant loss of 
lower motor neurons (fig. 13C). However, loss of skeletal muscle innervation was not 
significant until the OS stage of disease (fig. 13L). These observations suggest that: a) a 
compensatory mechanism exists to maintain skeletal muscle innervation during the loss of 
motor neurons between the PS and OS stages of disease; and b) the onset of hindlimb 
weakness is characterised not by the loss of motor neurons, but the loss of skeletal 
muscle innervation. Previous studies have demonstrated that collateral axon sprouting is a 
critical compensatory process in ALS (Gordon et al., 2004, Frey et al., 2000, Azzouz et al., 
1997, Shefner and Gooch, 2002, Aggarwal and Nicholson, 2002, Hansen and Ballantyne, 
1978), and is likely the compensatory mechanism observed in the SOD mice at the OS 
stage of disease. The onset of hindlimb weakness at the OS stage of disease therefore 
suggest the transition of the axon sprouting process from adaptive to maladaptive, which 
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leads to the accelerated progression of disease from the OS stage of disease onwards  
(Frey et al., 2000, Azzouz et al., 1997, Shefner and Gooch, 2002, Aggarwal and 
Nicholson, 2002, Hansen and Ballantyne, 1978). 
My results thus far converged on the conclusion that the OS stage of disease is a critical 
turning point in ALS disease progression, where mechanisms compensating for the 
gradual degeneration of motor neurons fail, and GH secretion increases. Spearman 
correlation analyses revealed a significant correlation between total, pulsatile, and MPP of 
GH secretion and skeletal muscle innervation in SOD mice at the OS stage of disease (fig. 
15; table 2). Meanwhile, there were no significant correlations between motor neuron 
counts with any of the parameters of pulsatile GH secretion (fig. 15; table 2). Together, 
these findings supported my hypothesis that the increase in GH at the OS stage of disease 
is a response to the loss of skeletal muscle innervation, and potentially a protective 
mechanism against the loss of motor function. The finding that GH secretion does not 
affect motor neuron survival (fig. 15; table 2) appeared to conflict with a previous study by 
Chung et al. (2015), where exogenous human GH treatment was protective against 
neurodegeneration in SOD mice. This contradiction may suggest profound difference in 
the effect of endogenous and exogenous GH, potentially due to alterations to feedback 
mechanisms regulating the GH/IGF-1 axis (fig. 5) when exogenous GH is introduced. This 
finding exemplifies the need to understand the impact of GH in a physiological system as a 
whole, and the significance of characterising the GH/IGF-1 axis and its associated 
components. 
In regards to the mechanism by which GH is maintaining neuromuscular function, it is 
currently still under speculation. As collateral axon sprouting is a known phenomenon in 
ALS (Gordon et al., 2004, Frey et al., 2000, Azzouz et al., 1997, Shefner and Gooch, 
2002, Aggarwal and Nicholson, 2002, Hansen and Ballantyne, 1978) and that GH can 
drive neuronal growth and regeneration (Asa et al., 2000, Andreassen and Oxlund, 2001, 
Bak et al., 1991, Beauville et al., 1992, Bratusch-Marrain et al., 1982, Bray, 1969, Brooks 
and Waters, 2010, Butler et al., 1991, Clemmons, 2004, Corpas et al., 1993, Dietz and 
Schwartz, 1991, Dunger et al., 1991, Fryburg et al., 1991, Fryburg et al., 1992, Garcia-
Aragon et al., 1992, Greenwood and Landon, 1966, Harvey et al., 2002, Hindmarsh et al., 
1987, Kraemer et al., 1992, Lichanska and Waters, 2008, Rizza et al., 1982), GH-induced 
axon sprouting is the most reasonable conclusion at present. The discrepancy of the loss 
of motor neurons without altering innervation may also be indicative of adaptive collateral 
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axon sprouting, as surviving neurons reinnervate lost connections (Brown et al., 1981). 
However, as no correlative assessments could be undertaken during the PS stage of 
disease where skeletal muscle innervation and GH secretion remained unchanged, it was 
impossible to determine whether GH was maintaining axon sprouting using the available 
data. Another potential mechanism that GH is maintaining motor function may be 
prolonging the survival of NMJs, but not creating new connections. The means under 
which GH maintains skeletal muscle innervation will therefore require further investigation, 
such as the use of electrophysiological techniques to estimate motor unit numbers (Ngo et 
al., 2012, Arnold et al., 2015), or retrograde tracers to map neuromuscular innervation 
(Bacskai et al., 2014, Naumann et al., 2000). 
 
4.3 The increase in growth hormone release at the onset of hindlimb weakness is not 
driven by changes to hypothalamic controls or alterations to skeletal muscle 
expression of growth hormone receptors. 
The conclusion that the rise in GH secretion is a protective mechanism against the loss of 
skeletal muscle innervation suggests a feedback link between GH secretion and NMJs. 
This feedback can loop back onto either the hypothalamus or the pituitary gland. Opposing 
my original hypothesis, assessment of mRNA expression of Srif and Ghrh revealed there 
was no significant change to the expression of the inhibitory Srif, but a decline in the 
stimulatory Ghrh (fig. 11, A & B). These results indicate that there was an overall reduced 
stimulatory response from the hypothalamus. As such, these results suggested that the 
increased GH secretion at the OS stage of disease was not driven by hypothalamic 
signals, and also that SOD mice – and potentially ALS patients – are already predisposed 
to GH suppression. Regardless of what drives this suppression of pro-GH secretory 
signals from the hypothalamus, the lack of hypothalamic stimulation suggest that the 
increased GH secretion may be due to a direct stimulation of somatotrophs in the pituitary 
gland (fig. 5). However, the absence of any significant difference in pituitary GH content in 
the SOD mice compared to age-matched WT controls from the PS to OS stages of 
disease (fig. 11C) indicates there was no change in the production of GH at the pituitary 
gland level at the OS stage of disease, despite the increase in GH release into circulation. 
However, this may not be an indication that pituitary GH production is unaltered. As GH 
content in the pituitary peaked at ages corresponding to the OS stage of disease for both 
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SOD and WT control mice, there is no evidence that pituitary GH content can increase any 
further, and any further increase in GH synthesis would be undetectable. There has yet to 
be research investigating the GH capacity in the pituitary gland, therefore will require 
future studies to address my hypothesis. Alternatively, GH levels in circulation may also be 
increased in SOD mice at the OS stage of disease without increasing pituitary production 
or hypothalamic stimuli, for example reducing GH clearance or increasing GH stability in 
circulation (i.e. binding proteins)(Mannor et al., 1991). These parameters will not be 
covered in this thesis though, and will require further investigations in the future. However, 
I demonstrated that the decline in pulsatile GH secretion at the ES stage of disease was 
associated with a decline in pituitary GH content (fig. 11C). Together with the observation 
that hypothalamic signals favour the suppression of GH secretion (fig. 11, A & B), these 
results suggest that the loss of the stimulation signal for GH secretion from the OS stage 
of disease may predispose SOD mice to the rapid decline in GH secretion as disease 
progresses. 
Subsequent to understanding the upstream signalling to GH secretion was whether GH 
signalling was affected. This was not only to understand whether the increase in GH 
secretion was indeed translating into the hypothesised growth and repair signals on NMJs, 
but may also further explain the mechanism which drives the GH increase at the OS stage 
of disease. As the reduced GH signalling due to GH-R loss can also lead to increased 
negative feedback to raise GH secretion (fig. 5), skeletal muscle GH-R expression was 
also determined in SOD and WT control mice. As hypothesised, assessment of both the 
protein and mRNA expression levels of GH-R in skeletal muscle revealed no significant 
changes throughout disease progression in SOD mice compared to age-matched WT 
controls (fig. 12). These results suggest that the ability of GH to act upon the skeletal 
muscles may not contribute to the increased GH secretion at the OS stage of disease in 
the SOD mice. This study did not investigate the sensitivity or the activation of the GH-R 
though, and therefore will require further investigations in the future to draw definitive 
conclusions. In summary, my current findings suggests that the increase in GH secretion 
at the OS stage of disease may be a result of changes to other circulating factors acting 
upon a regulatory feedback mechanism that influences GH secretion.  
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4.4 Growth hormone release in response to disease onset may act via the local 
production of insulin-like growth factor-1 in skeletal muscle. 
While GH may act on a self-regulatory negative feedback mechanism (fig. 5), a plethora of 
circulating factors may also act to regulate GH secretion. Of these, IGF-1 is immediately 
downstream to GH signalling, as well as the major mediator of the anabolic effects of GH 
(Daughaday et al., 1972, Brooks and Waters, 2010, Lichanska and Waters, 2008, Waters 
et al., 1999, Mavalli et al., 2010). Supporting my hypothesis, assessment of the circulating 
levels of IGF-1 (fig. 16A) and protein expression of both IGF-1Rα and IGF-1Rβ (fig. 16, C-
F) revealed no significant changes at the PS and OS stages of disease. The lack of 
change in both the availability of IGF-1 in circulation and the expression of IGF-1R 
subunits in skeletal muscles suggests that the increased GH secretion at the OS stage of 
disease was also not due to the increased feedback of IGF-1, nor signals downstream to 
IGF-1R. However, IGF-1R activation and subsequent signalling was not assessed in this 
study, therefore alterations to IGF-1R signalling cannot be concluded, and would require 
further investigations. Moreover, further research into the potential feedback links between 
skeletal muscles and GH secretion, such as inflammatory cytokines (Moreau et al., 2005) 
or lactate (Siciliano et al., 2002, Godfrey et al., 2009, Vadakkadath Meethal and Atwood, 
2012), may lead to further insights into ALS pathology.  
Finally, IGF-1 may still be the mediator of the hypothesised protective effects of GH on 
NMJs, as IGF-1 content within skeletal muscles of SOD mice was significantly elevated at 
the OS stage of disease when compared to age-matched WT controls (fig. 16B). This 
result provides evidence that GH may be acting through the local mIGF-1 to maintain 
neuromuscular function. However, the current study did not identify the mIGF-1 isoform 
previously shown to delay disease progression and extend survival in SOD mice 
(Dobrowolny et al., 2005). IGF-1 has multiple isoforms resultant from alternative splicing, 
with specialised structural and functional properties, such as their tissue specificity, 
responsiveness to GH, and biological response (Goldspink, 2005, Hill and Goldspink, 
2003, Tang et al., 2004). Further refining specific IGF isoforms and their respective 
signalling pathways will provide greater insight into the protective role of GH/IGF-1 
signalling in ALS. In particular, while this study focused on motor neurons and NMJs, 
pathological changes to skeletal muscles were largely marginalised. Future studies 
including assessments of skeletal muscle pathology may provide more conclusive results. 
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5 Chapter 5: Revised thesis approach and extended experiments 
5.1 Revision of aims and hypotheses 
Results presented thus far clearly demonstrate that the initial hypothesis that ALS is 
characterised only by growth hormone (GH) deficiency is untrue in the hSOD1G93A (SOD) 
mouse model. My results demonstrated that the onset of hindlimb weakness occurred in 
parallel with an increase in GH secretion relative to age-matched wild-type (WT) controls 
(fig. 9; table 1), suggesting that GH may play a protective role against ALS pathology. 
However, observations were only correlative, and I was unable to provide conclusive 
evidence that showed GH protected skeletal muscle innervation in SOD mice. I was also 
unable to determine whether the increase in GH secretion in SOD mice was pathologically 
driven, or rather a physiological response to the loss of skeletal muscle innervation. 
Finally, my observations that GH/IGF-1 seemed to be protective against ALS conflicts with 
clinical results from ALS patients that received GH treatments (Smith et al., 1993, Sacca et 
al., 2012). I therefore proposed that GH may also exert actions that negates its protective 
effects.  
The results presented thus far demonstrates the significance of the anabolic effects 
of GH/IGF-1 signalling in ALS. However, GH also heavily impacts the utilisation of energy 
within the body. GH promotes the use of lipids as the priority fuel source, while 
concomitantly promoting an overall increase in energy utilisation (Møller and Jørgensen, 
2009, Mavalli et al., 2010, Short et al., 2008, Bray, 1969). GH also inhibits the use of other 
energy sources such as glycogen and protein (Bray, 1969, Hussain et al., 1994, Møller 
and Jørgensen, 2009, Meller et al., 1993, Ho et al., 1988b, Trenkle, 1970, Hartman et al., 
1992). The preservation of glycogen and protein sustains muscle function during periods 
of negative energy balance - where energy utilisation is greater than energy intake and 
storage (Bray, 1969, Hussain et al., 1994, Møller and Jørgensen, 2009, Meller et al., 1993, 
Ho et al., 1988b, Trenkle, 1970, Hartman et al., 1992). In addition to its direct effects, GH 
also alters energy balance by inhibiting the production and signalling of insulin (Rizza et 
al., 1982, Hussain et al., 1994, Trimble et al., 1980, Hansen et al., 1986, Bratusch-Marrain 
et al., 1982, Rizza, 1982, Meller et al., 1993, Dominici and Turyn, 2002, Bak et al., 1991), 
a hormone that promotes glucose storage into fat (Kido et al., 2001, Plum et al., 2006, 
Koyama et al., 1997, Brehm et al., 2006, Rhodes and White, 2002). Increases in GH levels 
thus reduces energy storage and further reduces fat stores. Emerging evidence suggests 
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that body weight and fat storage are independent prognostic predictors of ALS. Paganoni 
et al. (2011) collated ALS subjects from three clinical trial databases (n = 427) and 
revealed that patients with greater body mass index (BMI) at the time of diagnosis 
generally had greater survival probability – with the exception of the morbidly obese (fig. 
17). These results suggested the possibility that increasing internal energy stores may 
prolong survival in ALS. Furthermore, Wills et al. (2014) significantly extended survival in 
ALS patients (n = 6-8) by intervening with hypercaloric diets (fig. 18). Taken together, 
these results signify that maintaining sufficient energy stores within the body is critical in 
ALS patients. The ability of GH to promote energy utilisation therefore suggests that GH 
treatment may be detrimental to ALS patients.  
 
 
 
Figure 17: Correlation between BMI, and survival in amyotrophic lateral sclerosis 
patients. Kaplan–Meier survival curves of 427 amyotrophic lateral sclerosis (ALS) 
patients stratified according to their body mass index (BMI). The survival curves were 
truncated at 764 days (Modified from Paganoni et al., 2011). 
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Figure 18: Hypercaloric nutrition and survival in amyotrophic lateral sclerosis 
patients. Kaplan-Meier curves for overall survival of amyotrophic lateral sclerosis (ALS) 
patients after randomised allocation of three dietary interventions: high-carbohydrate/ 
hypercaloric diet (HC/HC, n = 8); high-fat/ hypercaloric diet (HF/HC, n = 6); and control 
diet (n = 6). (Reproduced from Wills et al., 2014). 
 
In summary, understanding the balance between anabolic and energy metabolic 
effects of GH/IGF-1, and how they impact ALS pathology, may yield insights into why past 
clinical trials have failed, and potentially develop new therapies. As such, new aims and 
experiments were developed to address these new observations. 
 
Aim 3: To determine whether impaired growth hormone signalling accelerates disease 
progression and reduces survival in the hSOD1G93A mouse model of ALS. 
Aim 3 rationale: 
The significant positive correlation between GH secretion and skeletal muscle innervation 
in SOD mice at the OS stage of disease (fig. 15; table 2) led to the hypothesis that GH 
may be released in response to pathology as a protective/compensatory mechanism. To 
test this hypothesis, SOD mice with impaired growth hormone receptor (GH-R) signalling 
were generated. If my hypothesis holds true, the SOD mice with impaired GH-R signalling 
would lose the protective support of GH, leading to accelerated onset of motor 
impairments and reduced survival. In addition, given the conflict between my results, that 
suggests GH plays a protective role in ALS, and clinical trials that report ALS patients 
gaining no benefit from GH treatment (Sacca et al., 2012, Smith et al., 1993), I proposed 
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that GH may also exert actions that negates its protective effects. As GH promotes fat 
utilisation (Møller and Jørgensen, 2009, Mavalli et al., 2010, Short et al., 2008, Bray, 
1969), I anticipated that increasing GH levels would lead to a reduction in fat storage, 
thereby negating its protective effects. As such, I hypothesised that SOD mice with 
impaired GH-R signalling would have greater fat stores when compared to SOD mice with 
normal GH-R signalling. 
To address aim 3, two experiments were devised: 
Experiment 5: Determine whether the symptomatic disease duration and survival of 
hSOD1G93A mice with impaired growth hormone receptor signalling is 
reduced. 
Experiment 6: Determine whether the histopathological and fat distribution profiles 
of hSOD1G93A with impaired growth hormone receptor signalling reflect 
a more severe pathological state. 
 
Aim 4: To determine whether the observed relationships between growth hormone and 
skeletal muscle innervation loss in the hSOD1G93A mouse model of ALS is resultant 
from pathology. 
Aim 4 rationale: 
There have been no studies that detail the relationship between GH and skeletal muscle 
innervation in adult mammals. Given my observations suggesting GH to be a protective 
agent against the loss of skeletal muscle innervation in SOD mice, I sought to determine 
whether this was a pathological response. If the correlation between GH and innervation at 
the OS stage of disease (fig. 15; table 2) is indeed a pathological response unique to ALS, 
it may lead to insights into the development of biomarkers and therapeutics for ALS. In 
addition, the ubiquitousness of the effects of GH may further the current understanding of 
ALS pathology; knowledge which is still severely lacking. To address this aim, advance 
aged WT mice were used to study the relationship between motor neuron numbers, 
skeletal muscle innervation, and GH/IGF-1. The choice of aged WT mice stems from the 
natural age-associated decline in neuromuscular function. This decline in neuromuscular 
function, known as sarcopenia, serves as the best model of a non-pathological loss of 
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neuromuscular function. If the same relationship between GH secretion and skeletal 
muscle innervation is not observed in the aged mice, it provides evidence to suggest that 
the increased GH secretion at the OS stage of disease in SOD mice is a pathological 
process. 
To address aim 4, three experiments were devised: 
Experiment 7: Determine the pulsatile GH secretion profile of wild-type C57Bl/6J 
(non-diseased control) mice throughout ageing. 
Experiment 8: Determine the circulating and skeletal muscle-specific insulin-like 
growth factor-1 levels of wild-type C57Bl/6J (non-diseased control) mice 
throughout ageing. 
Experiment 9:  Determine the Status of skeletal muscle innervation and motor 
neuron number of skeletal muscles of wild-type C57Bl/6J (non-diseased 
control) mice during advanced ageing, and their relationship with growth 
hormone, insulin-like growth factor-1, and adiposity. 
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6 Chapter 6: Methods – Part two 
6.1 Animals 
To determine the role of growth hormone (GH) signalling in hSOD1G93A (SOD) mice, SOD 
mice were cross-bred with a transgenic mouse strain with impaired signalling in the growth 
hormone receptor (GH-R) – the GHR391 (391) – to generate the SOD391 mouse. The 391 
mouse is a transgenic mouse with a knock-in deletion of the residues distal to m391 of the 
GH-R first generated by Rowland et al. (2005). This deletion results in the loss of multiple 
signalling domains (fig. 19A), most notably signal transducer and activator of transcription 
5 (STAT5). STAT5 signalling is critical in the anabolic effects of GH in postnatal growth, 
particularly the promotion of IGF-1 transcription. The 391 mouse therefore has less than 
10% the levels of IGF-1 production compared to age-matched WT controls (fig. 19B). The 
cross-breeding of the SOD and 391 mice results in six genotypes (table. 3). Only male 
mice were used in this study. 
 
Figure 19. Phenotypical characteristics of the growth hormone receptor-
truncated GHR391 mouse. Knock-in deletion of the residues distal to m391 of the 
growth hormone receptor (GH-R) (A). This includes the complete abolishment of 
STAT5 signalling in GHR391 homozygous mice (391), which significantly impairs 
insulin-like growth factor-1 (IGF-1) production (B). (Modified from Rowland et al., 
2005). 
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Table 3. SOD391 mice genotypes. Punnett illustrating the six possible genotypes of 
the cross-breeding of the hSOD1G93A mouse model of ALS and the GHR391 growth 
hormone receptor truncated mouse. 
  GHR391 
  391+/+ 391+/- 391-/- 
hSOD1G93A 
WT WT WT391+/- WT391-/- 
SOD SOD SOD391+/- SOD391-/- 
 
 
6.2 Assessment of motor function and survival 
To characterise the changes to motor function, SOD391 mice were monitored weekly for 
changes in several test parameters. The parameters investigated included phenotype 
assessment, hind limb grip strength, and rotarod treadmill test. Following weaning (35 
days of age), animals were group-housed according to gender with littermates. Following 4 
days of acclimation (39 days of age), animals were trained to perform the hind limb grip 
strength and rotarod test for two consecutive days (40-41 days of age). First official 
measurements were made from 42 days of age. Measurements were recorded weekly 
thereafter. This study was performed blind to eliminate observer bias that may influence 
the legitimacy of the findings. Phenotype onset in all categories were defined as the first 
time point where a significant divergence between the SOD391 mice and their WT 
counterparts were observed, i.e. WT vs SOD, WT391+/- vs SOD391+/-, and WT391-/- vs 
SOD391-/-. Significance between each genotype was determined by multiple T tests 
through GraphPad Prism v6.07, and corrected for multiple comparisons using the Holm-
Sidak method. A P value ≤ 0.05 was considered to be significant. 
 
6.2.1 Phenotype assessment 
Phenotype was determine through three observable traits, and graded based on severity 
(table 4). The total score (max. 8) was then recorded. The end-point for survival was also 
determined by the loss of the righting reflex within 30 seconds (score = 2). 
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Table 4. Assessment criteria for phenotype score in behaviour and survival 
assessment 
Phenotype 
Phenotype score 
0 1 2 
Hind limb splay 
(per leg) 
Normal splay 
response following 
suspension from 
tail (fig. 20A) 
Difficulty 
maintaining splay 
response and/or 
tremors 
Incapable of hind 
limb splay (fig. 
20B) 
Gait 
Normal gait 
without difficulty 
Tremors and/or 
difficulty walking 
Hind limbs 
incapable of 
propulsion 
Righting reflex  
(after being flipped 
onto their back) 
Unable to flip/ 
immediate righting 
Delayed righting 
Unable to right 
within 30 secs 
(survival end-
point) 
 
 
Figure 20. Loss of hind limb splay in hSOD1G93A mice. Representative photos of 
asymptomatic (score = 0) (A) and late symptomatic (score = 2) (B) hSOD1G93A mice. 
 
6.2.2 Hind limb grip strength 
Hind limb grip strength was determined using a mouse grip strength meter (Ugo Basile, 
cat#47200). Each mouse was first positioned onto the force transducer as shown in figure 
21. The tail was then gripped between the thumb and middle finger, while the index finger 
rests on the dorsal side of the tail (fig. 21). The mouse was then pulled at a ~35o angle 
backwards until both hind limbs released from the grasping T-bar of the force transducer 
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by holding point A fixed and depressing point B (fig. 21). The maximum force of ten pulls 
was then recorded for each animal. 
 
 
 
Figure 21. Positioning of mouse on force transducer of grip strength meter. The 
mouse is positioned with both hind feet grasping the grasping T-bar of the force 
transducer, and the tail resting at the centre. Red lines indicate the contact points for 
the thumb and middle finger (A) and the index finger (B). 
 
6.2.3 Rotarod treadmill test 
The rotarod treadmill test tasks the animals to stay atop a rotating beam to test motor 
function. Each mouse was left on a rotarod treadmill (Ugo Basile, cat#57601) for 240 secs 
running at 20 rpm (fig. 22). Animals that fail to complete the task were given three attempts 
in total, separated by 1 min rests in between. The longest time of the attempts was 
recorded. 
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Figure 22. Positioning of the mouse in the rotarod treadmill. The rotarod 
treadmill features a central rotating cylinder wrapped by an uneven rubber lining to 
provide grip, and separated into five independent chambers. Each chamber is 
monitored by a timer with a magnetic trigger, which is activated upon lifting the trip 
plate. As the mice fall from the rotarod treadmill, the trip plate is lowered, causing the 
timer to pause. 
 
6.3 Assessment of the histopathological hallmarks of ALS 
Motor neuron numbers and neuromuscular junction innervations were determined as 
previously described in section 2.6. 
 
6.4 Assessment of energy metabolic profile 
6.4.1 Assessment of adiposity 
Adiposity was assessed by determining the weight of three major adipose tissue 
reservoirs: the perigonadal, subcutaneous, and subscapular fat pads (fig. 23). Fat pads 
were collected via dissection following euthanasia. A small incision was first made through 
the skin on the ventral portion of the midriff. Retraction of the skin reveals the 
subcutaneous fat pads behind the thighs, and the subscapular fat pad beneath the 
scapular (fig. 23). Abdominal muscles are then severed to reveal the peritoneal cavity. The 
perigonadal fat pads (fig. 23) are revealed following identification of the testes and 
epididymis (male) or fallopian tubes (female). All fat pads were weighed on a fine scale 
immediately after exposure to air to reduce interference due to dehydration. Perigonadal 
fat is comprised predominantly of white adipose tissue (WAT), and makes up the most 
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abundant tissue of fat mass in mice (Casteilla et al., 2008). Perigonadal fat was therefore 
used as a proxy for overall adiposity in the mice. 
 
Figure 23. Graphic illustration of the adipose tissue reservoirs in C57Bl/6J 
mice. Representative positioning of the subscapular fat pad, subcutaneous fat pad, 
and perigonadal fat pads.  
 
6.4.2 Energy metabolism-related hormones 
To investigate the changes to hormones that impact energy metabolism – specifically 
insulin, glucagon, and leptin – the mouse metabolic magnetic bead panel – Milliplex Map 
Kit (Merck Millipore; cat# MMHMAG-44K) was used to determine multiple circulating 
hormone levels within the animals. Plasma samples were first prepared as mentioned 
previously (section 2.3.3). Prior to the performance of the assay, 0.5 µl DPPIV inhibitor 
(Merck Millipore; cat# DPP4), 1 µl diluted (1:10) protease inhibitor cocktail (cOmplete™, 
Mini, Roche, CHE; cat# 11836153001), and 1 µl aprotoninin (Sigma-Aldrich, USA; cat# 
A6279) were added per every 50 µl plasma sample.  Prior to sample loading, an 8-point 
standard curve was first generated using Mouse Metabolic Hormone Standard (Merck 
Millipore; cat# MMH-8044) by three-fold serial dilution with assay buffer (Merck Millipore; 
cat# LE-ABGLP)(insulin & leptin: 50 000 pg/ml – 69 pg/ml; glucagon: 10 000 pg/ml – 14 
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pg/ml; plus blank). Using a 96-well black plate, 200µl of assay buffer was first loaded into 
all wells and shaken at RT for 10 mins to moisturise the surface, which was then decanted. 
10 µl serum mix (Merck Millipore; cat# LRGT-SM) was then loaded into all wells, while 
another 10 µl assay buffer was loaded into the blank and sample wells. 10 µl of each 
standard, quality control (Merck Millipore; cat# MMH-6044), and sample were then loaded 
into the appropriate wells. 25 µl of a mixture of antibody-immobilised beads coated with 
anti-insulin (Merck Millipore; cat# RMINS-MAG), anti-glucagon (Merck Millipore; cat# 
RMGLU-MAG), and anti-leptin (Merck Millipore; cat# RMLPTN-MAG) antibodies in bead 
diluent (Merck Millipore; cat# LE-BD) was then added to all wells. The plate was then 
sealed and incubated at 4 ⁰C with agitation on a plate shaker overnight. After the overnight 
incubation, the plate was washed three times with wash buffer on a hand held magnetic 
separation block (Merck Millipore; cat# L-WB) to ensure retention of the antibody-
immobilised beads. 50 µl of detection antibodies (Merck Millipore; cat# MMH-1044-2) were 
added to each well following washing. The plate was then sealed and placed on a plate 
shaker at RT for 30 mins. An additional 50 µl of streptavidin-phycoerythrin (Merck 
Millipore; cat# L-SAPE12) was added to each well before being resealed and returned to 
the shaker at RT for another 30 mins. After another three washes on the hand held 
magnetic separation block, 100 µl of drive fluid (Luminex, USA; cat# MPXDF-4PK) was 
added to all wells, then placed on a plate shaker for 5 mins to resuspend the antibody-
immobilised beads. Finally, the plate was run plate on a MAGPIX system (Luminex, USA; 
cat# MAGPIX-XPONENT) running xPONENT software. Hormone concentration was 
determined via the median fluorescence intensity (MFI) using a 5-parameter logistic or 
spline curve-fitting method of the respective standard curves. 
 
6.5 Statistical analyses 
Prior to statistical analysis, NMJ percent innervation was first expressed through an 
arcsine transformation (arcsin(x)) to stabilise variance for analysis. Results of the separate 
age groups within and between the different genotype groups, including the aged WT 
mice, were analysed in GraphPad Prism v6.07 using one-way ANOVA. The point of 
divergence regarding assessment of motor function was determined using multiple T-tests. 
Survival analysis was conducted using the log-rank test and Gehan-Breslow-Wilcoxon 
method. All results were presented as mean ± SEM unless otherwise specified. 
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Nonparametric Spearman correlation was also employed to determine the correlation 
between pulsatile GH secretion and the histopathological hallmarks of ALS in the SOD 
mouse model, whereby a Bonferroni correction was calculated based on α = 0.05; a P 
value of ≤ 0.05 was accepted as significant in all other reported results. A P value of ≤ 0.05 
was accepted as significant in all reported results. 
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7 Chapter 7: Results – Part two  
7.1 Experiment 5: Disease progression and survival of hSOD1G93A with impaired growth 
hormone receptor signalling 
The novel finding that GH secretion increases at the onset of hindlimb weakness (fig. 9; 
table 1) and correlates to skeletal muscle innervation (fig. 15; table 2), suggests that GH 
may play a protective role against the degeneration of neuromuscular function. As such, it 
was hypothesised that the loss of the protective effects of GH would lead to detrimental 
effects on animal models of ALS; potentially extending to patients. To address this, SOD 
mice with impaired GH-R signalling – the SOD391 mice – were generated to further define 
the role of GH in the SOD mouse model of ALS. To establish how impairing GH signalling 
affects disease progression, I first characterised weekly changes to motor function, as well 
as survival. It was hypothesised that SOD391 mice would have significantly earlier onset 
of motor impairments, accompanied by rapid progression and reduced survival. 
 
7.1.1 Impaired growth hormone receptor signalling in hSOD1G93A mice delays motor 
symptom onset, but does not alter survival. 
Weekly measures revealed that there were significant delays in grip strength (12 wks)(fig. 
24A), phenotype score (10 wks)(fig. 24B), and rotarod time (12 wks)(fig. 24C) in SOD391-/- 
mice compared to SOD mice. Interestingly, SOD391+/- mice did not exhibit any significant 
differences in any measure of motor symptoms compared to SOD mice (fig. 24), 
suggesting that partial impairments to GH-R signalling is sufficient to affect motor function. 
Results also revealed that despite the significant delays in motor symptom onset, survival 
was unaltered in either SOD391+/- or SOD391-/- mice compared to SOD mice (fig. 25).  
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Figure 24. Onset of motor function degeneration was significantly delayed in 
SOD391-/- compared to hSOD1G93A and SOD391+/- mice. Onset of the loss of mean 
base-line normalised hind limb grip strength (A), phenotype score (B), and rotarod 
performance time (C). Values are expressed as mean values. A value of P ≤ 0.05 
was accepted as significant; n = 8-20/genotype. 
 
 
Figure 25. Survival was unchanged in SOD391 mice. Survival analysis using the 
log-rank test and Gehan-Breslow-Wilcoxon method revealed no significant changes 
to survival in SOD, SOD391+/-, and SOD391-/-. A value of P ≤ 0.05 was accepted as 
significant; n = 8-20/genotype. 
 
7.2 Experiment 6: Histopathological and fat distribution profile of hSOD1G93A with 
impaired growth hormone receptor signalling. 
Contrary to my initial hypothesis, the onset of hindlimb weakness did not occur earlier in 
SOD391 mice compared to SOD mice, and was in fact significantly delayed (fig. 24). I 
previously proposed that GH may negate its protective effects by reducing fat storage, 
which was proposed to negatively impact ALS prognosis (Paganoni et al., 2011, Wills et 
al., 2014). The observation that SOD391 mice had a significantly delayed disease onset, 
created an opportunity to determine whether the negative impact GH makes on energy 
stores outweigh its protective anabolic effects on degenerating tissue. To address this, I 
determined the histopathological changes to skeletal muscle innervation and motor 
neurons, as well as the changes to adiposity in the SOD391 mice, and compared them to 
age-matched controls. It was hypothesised that skeletal muscle innervation would be 
significantly retained in SOD391 mice compared to age-matched SOD mice at ages 
corresponding to the OS stage of disease, whereas motor neuron number will remain 
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unchanged. It was also hypothesised that adiposity would be significantly greater in 
SOD391 mice compared to age-matched SOD mice.  
 
7.2.1 Impaired growth hormone receptor signalling in SOD391 mice protects against 
motor neuron loss, but not skeletal muscle innervation 
Based on observations that disease onset is delayed in SOD391 mice (fig. 24), 
assessment of histopathology was focused at 125 days of age, which corresponded to the 
MD stage of disease in SOD mice. As expect, results revealed no significant loss of NMJ 
innervation (fig. 26A) nor motor neurons (fig. 26B) in WT391 mice compared to WT mice, 
revealing that the 391 mutation does not affect neuromuscular development. However, it 
was also revealed that skeletal muscle innervation was not altered between SOD391 and 
SOD mice at 125 days of age (fig. 26A). Yet another contradiction to the initial hypotheses, 
motor neuron numbers – which previously showed no association with GH secretion in 
SOD mice (fig. 15; table 2), was retained in SOD391-/- mice compared to WT controls (WT 
and WT391) at 125 days of age (fig. 26B). While motor neuron number is maintained in 
the SOD391-/- (fig. 26B), skeletal muscle innervation was unaltered (fig. 26A), implying that 
any benefits brought upon the 391 mutation on motor neurons does not ultimately translate 
to greater skeletal muscle innervations. 
 
Figure 26. GHR391 mutation in hSOD1G93A mice protects against motor neuron 
loss. Percent neuromuscular junction (NMJ) innervation (A) and motor neuron counts 
(B) were used as histological indicators of motor function in SOD391 mice. Percent 
NMJ innervation (B) was not significantly altered in SOD391 mice compared to 
hSOD1G93A (SOD) mice. By contrast, motor neuron counts (B) in SOD391-/- mice was 
maintained compared to age-matched WT and WT391 mice. Values are expressed 
as mean ± SEM. A value of P ≤ 0.05 was accepted as significant; n = 4/genotype. 
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7.2.2 Subcutaneous fat mass significantly greater in SOD391-/- mice compared to 
hSOD1G93A mice. 
Adiposity was assessed in the SOD391 mice based on three major fat deposits: 
subcutaneous (fig. 27A), subscapular (fig. 27B), and perigonadal (fig. 27C). When 
compared to the WT counterparts, adiposity of SOD391 mice did not differ significantly at 
70 days of age, which corresponded to the OS stage of disease in SOD mice (fig. 27). 
Interestingly, by 125 days of age, SOD391-/- mice exhibited significant increases in 
subcutaneous fat mass relative to body length when compared to SOD mice (fig. 27A). 
This rapid increase in adiposity in the SOD391-/- mice provides support to the hypothesis 
that altered energy homeostasis underlies the delayed onset of disease observed 
previously (fig. 24). 
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Figure 27. Fat distribution in SOD391 mice. Adiposity was assessed by the relative 
mass of the subcutaneous (A), subscapular (B), and perigonadal (C) fat pads of the 
mice. Adiposity was not significantly different at 70 days of age between genotypes 
after correction to body length. At 125 days of age, SOD391-/- mice possess a 
significantly greater proportion of subcutaneous fat after correcting to body length 
compared to SOD mice. Perigonadal fat mass also significantly increased from 70 to 
125 days of age in wild-type control mice. Values are expressed as mean ± SEM. A 
value of P ≤ 0.05 was accepted as significant; n = 4-18/genotype. #Significant 
difference compared to younger counterpart of the same genotype. 
 
7.3 Experiment 7: The pulsatile growth hormone secretion profile of wild-type C57Bl/6J 
(non-diseased control) mice throughout ageing. 
The discovery of the positive correlation between GH secretion and skeletal muscle 
innervation (fig. 15; table 2) led to the query of whether the increase of GH was a 
pathological response to disease, or a physiological response to the loss of innervation. 
The distinction of the increase in GH secretion being pathological may provide further 
insights into ALS as a disease, as well as the potential of GH and GH-associated factors 
as ALS biomarkers and therapeutic targets. In light of this, a mouse model exhibiting 
neuromuscular degeneration was needed. However, this neuromuscular degeneration 
must also not be associated with disease or trauma, as both situations impact physiology 
(Tenore et al., 1977, Wang et al., 1992, Desborough, 2000, Melarvie et al., 1995) and 
would prevent accurate findings. As such, old aged WT C57Bl/6J mice were used to study 
the relationship between GH secretion and skeletal muscle innervation under non-
pathological conditions. This was achievable as advanced ageing in all mammals is 
associated with a process known as sarcopenia (Frontera et al., 2000b, Iannuzzi-Sucich et 
al., 2002, Marzetti et al., 2009, Morley et al., 2001, Vandervoort, 2002). Sarcopenia is the 
non-pathological degeneration of skeletal muscle mass and function in response to ageing 
(Iannuzzi-Sucich et al., 2002). The loss of neuromuscular function leads to gradual 
disability and eventual loss of independence in the elderly (Morley et al., 2001, 
Vandervoort, 2002, Winograd et al., 1991, Baumgartner et al., 1998). Sarcopenia is 
characterised by the loss of muscle quality, mass, and strength, due to the loss of skeletal 
muscle innervation, capillary density, and loss of muscle fibres (Iannuzzi-Sucich et al., 
2002, Frontera et al., 2000a, Vandervoort, 2002, Grimby and Saltin, 1983). The loss of 
production and responsiveness to trophic hormones, such as GH, may be a causal factor 
of sarcopenia (Rudman, 1985, Morley et al., 2001). The use of aged mice undergoing 
sarcopenia provides a unique opportunity to study neuromuscular degeneration in the 
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most physiologically neutral environment. However, in order to understand the relationship 
between GH and skeletal muscle in sarcopenia, I first needed to establish how pulsatile 
GH secretion is altered in WT mice. Though it has been long speculated that GH signalling 
declines in old age (Finkelstein et al., 1972), detailed measures within humans and animal 
models are lacking. GH levels vary greatly across individuals, and subjective to internal 
and environmental factors, such as age, sex, activity, stress, diet, circadian rhythm, and 
disease (Martin et al., 1997, Ho et al., 1988a, Ho et al., 1987, Tenore et al., 1977, Shuster 
et al., 1995, Kraemer et al., 1992, Greenwood and Landon, 1966, Seggie and Brown, 
1975). Evidence based upon the comparison of randomly selected, differentially-aged 
cohorts are therefore unreliable. Rather than taking discrete measures across a 
population, sequential analyses across individual development were necessary to properly 
conclude the progressive changes in GH during ageing. The first study into understanding 
the role of the relationship between GH and neurodegeneration in sarcopenia was 
therefore to characterise the progressive changes to pulsatile GH secretion throughout 
ageing in WT mice. Based on previous observations presented in this thesis (fig. 9; table 
1), and past studies suggesting that mammalian GH levels declines in old age, it was 
hypothesised that pulsatile GH secretion would progressively decline after the pubertal 
growth spurt, at 5 weeks of age. 
 
7.3.1 Significant age-associated decline in pulsatile growth hormone secretion following 
maturation into adulthood. 
To accurately assess age-associated changes to pulsatile GH secretion in WT mice 
throughout ageing, pulsatile GH secretion was determined in the same individual mice 
throughout their lifetime, at 5, 10, 17, 24, 52, 78, and 104 weeks of age. This was to 
eliminate any variation that could be introduced due to individual variability between 
animals. Pulsatile GH secretion was greatest at 5 weeks of age (fig. 28A; table 5), when 
mice are still experiencing the pubertal growth spurt (fig. 10). This was followed by a 
gradual decline from 10 to 24 weeks of age (fig. 28, B, C, D, & H; table 5). From 52 
through to 104 weeks of age, GH secretion reaches a plateau, and exhibits significantly 
reduced GH levels (fig. 28, E-H; table 5). The decline in GH secretion was attributed to 
both the decline in GH secretion within each GH pulse and the basal GH secretion, but not 
pulse frequency (table 5). These results established the first detailed record of an age-
dependent decline in the pulsatile secretion of GH in mice throughout life. 
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Figure 28. Progressive decline in pulsatile growth hormone secretion in wild-
type C57Bl/6J mice throughout life. Representative pulsatile growth hormone (GH) 
secretion profiles of the same C57Bl/6J (WT) mice at 5 (A), 10 (B), 17 (C), 24 (D), 52 
(E), 78 (F), and 104 (G) weeks of age. Samples were collected for 6 hours at 10-
minute intervals starting from 0700 hrs (30 mins after the initiation of the light cycle). 
A regular periodicity of pulsatile GH secretion was characterised by peak secretion 
periods dispersed between stable low baseline secretion periods. Pulsatile release of 
GH secretion gradually declined from 5 through to 24 weeks of age, where GH 
secretion then remained low until 104 weeks of age (H). Deconvolution analysis data 
summarised in table 5. 
 
 
Table 5: Deconvolution analysis parameters of pulsatile growth hormone 
secretion from wild-type C57Bl/6J mice throughout life. Deconvolution analysis 
parameters of pulsatile growth hormone (GH) secretion in C57Bl/6J mice at 5, 10, 17, 
24, 52, 78, and 104 weeks of age. 
 
For GH, samples were collected at 10-minute intervals between 0700 hrs and 1300 hrs. Data are presented as mean ± 
SEM, *P ≤ 0.05 was considered significant; n = 6. 
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7.4 Experiment 8: Circulating and skeletal muscle-specific insulin-like growth factor-1 
levels in wild-type C57Bl/6J (non-diseased control) mice throughout ageing. 
In order to study whether the increase in GH secretion in response to the loss of skeletal 
muscle innervation (fig. 15; table 2) was a pathological response in SOD mice at the onset 
of hindlimb weakness, I needed to understand the relationship between neuromuscular 
function and GH secretion under physiological conditions. In order to address this, I 
adopted aged WT mice where I anticipated a natural decline in neuromuscular function, 
which may be influenced, or is influenced by, age-associated changes to GH secretion 
(Rudman, 1985, Morley et al., 2001). Characterisation of the pulsatile GH secretion profile 
of WT mice confirmed the gradual decline in GH secretion throughout life following puberty 
(fig. 28; table 5). It was also previously hypothesised that GH acts through muscle-specific 
IGF-1 (mIGF-1) to drive skeletal muscle innervation in SOD mice at the onset of hindlimb 
weakness. Therefore, to further establish comparisons between the pathology observed in 
SOD mice and sarcopenia in WT mice, I determined the changes to IGF-1 levels in WT 
mice throughout life. It was hypothesised that mIGF-1 would reflect the decline in pulsatile 
GH. Given the lack of change observed so far in WT mice at ages corresponding to 
different disease stages in SOD mice (fig. 16A), it was also hypothesised that circulating 
IGF-1 would remain unchanged throughout life. 
 
7.4.1 Age-associated changes to pulsatile growth hormone secretion coincides with 
skeletal muscle-specific insulin-like growth factor-1 throughout ageing, but not 
circulating insulin-like growth factor-1. 
To further understand the downstream effects of the chronic decline in GH secretion in 
ageing mice, I investigated the changes to skeletal muscle-specific and circulating levels of 
IGF-1 in a separate cohort of animals at the same ages. As hypothesised, results showed 
that circulating IGF-1 levels were unaltered from 5 through to 104 weeks of age (fig. 29A). 
By contrast, mIGF-1 levels progressively declined in an age-dependent fashion, reflecting 
the reduction in GH secretion (fig. 29B). Under the assumption that circulating IGF-1 acts 
primarily as a negative feedback signal on the GH/IGF-1 axis (Sjögren et al., 1999), these 
results suggest that the decline in GH secretion is also accompanied by a decline in the 
requirement of the activation of the GH/IGF-1 axis. Interestingly, there was a marginal 
increase in mIGF-1 at 104 weeks of age (fig. 29B). This increase in mIGF-1 raises the 
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question of whether it may be associated with the loss of neuromuscular function at the 
latter stages of life in the WT mice. 
 
Figure 29. Circulating and skeletal muscle-specific levels of insulin-like growth 
factor-1 in wild-type C57Bl/6J mice throughout life. Circulating insulin-like growth 
factor-1 (IGF-1) levels (A) remained unchanged from 5 through to 104 weeks of age 
in C57Bl/6J mice. Skeletal muscle-specific IGF-1 (muscle IGF-1) levels (B) exhibited 
an age-associated decline from 5 through to 76 weeks of age, before increasing 
again at 104 weeks of age. Values are expressed as mean ± SEM. A value of P ≤ 
0.05 was accepted as significant; n = 6-9/group. 
 
7.5 Experiment 9: Status of skeletal muscle innervation and motor neuron number of 
skeletal muscles of wild-type C57Bl/6J (non-diseased control) mice during advanced 
ageing, and their relationship with growth hormone, insulin-like growth factor-1, and 
adiposity. 
The goal for the series of experiments investigating the GH/IGF-1 and fat distribution 
profile of ageing WT mice was to understand their relationship with neuromuscular 
function, which may identify whether the proposed protective properties of GH on skeletal 
muscle innervation in SOD mice was a pathological response. To address this, motor 
neuron numbers and skeletal muscle innervation were also assessed in the aged WT 
mice. Given that sarcopenia is a known phenomenon in mammals (Frontera et al., 2000b, 
Iannuzzi-Sucich et al., 2002, Marzetti et al., 2009, Morley et al., 2001, Vandervoort, 2002, 
Grimby and Saltin, 1983), it was hypothesised that neuromuscular function would decline 
rapidly in old age. This would therefore be reflected in a reduction in motor neuron 
numbers as well as skeletal muscle innervation (Grimby and Saltin, 1983). 
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7.5.1 Advanced ageing is accompanied by the loss of motor neurons in wild-type 
C57Bl/6J mice. 
Motor neuron number and NMJ innervation in WT mice were assessed at 52 through to 
104 weeks of age – where changes to motor function were hypothesised to most likely to 
occur. There was no change in NMJ innervation or motor neuron number from 52 to 78 
weeks of age (fig. 30, A & B). However, nearing the life expectancy of C57Bl/6J mice 
(Rowlatt et al., 1976), there was a significant reduction in percent NMJ innervation at 104 
weeks of age (0.925 ± 0.031) compared to 52-  (0.990 ± 0.005) and 76- (0.993 ± 0.007) 
weeks of age in WT mice (fig. 30A); though motor neuron numbers were still unchanged 
(fig. 30B). 
 
Figure 30. Percent neuromuscular junction innervation of the 
gastrocnemius muscle and motor neuron number in aged wild-type 
C57Bl/6J mice. Gastrocnemius muscle innervation (A) remained undisrupted in 
aged animals at 52 and 78 weeks of age. At 104 weeks of age, there is a 
significant reduction in percent NMJ innervation. In contrast, the number of 
motor neurons (B) remained unchanged 52 through to 104 weeks of age. 
Values are expressed as mean ± SEM. A value of P ≤ 0.05 was accepted as 
significant; n = 6-9/group. 
 
7.5.2 Loss of innervation in wild-type C57Bl/6J mice at 104 weeks of age was not 
associated with total growth hormone secretion or muscle-specific insulin-like 
growth factor-1.  
Assessment of NMJ innervation in the gastrocnemius muscles revealed that WT mice 
maintained complete NMJ innervation until 104 weeks of age (fig. 31A). In light of this, 
assessment of the factors influencing NMJ innervation and motor neuron counts were 
limited to animals at 104 weeks of age. Correlation analyses revealed no significant 
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relationships between total GH secretion and mIGF-1 with percent NMJ innervation and 
motor neuron counts (fig. 31, A & C; table 6). Taken together, these results reveal that 
there is no association between innervation and total GH secretion or mIGF-1 in advance 
aged WT mice. 
 
Figure 31. Percent neuromuscular junction innervation of the gastrocnemius 
muscle and motor neuron number is not associated with total growth hormone 
release nor muscle-specific insulin-like growth factor-1 in aged wild-type 
C57Bl/6J mice. Total growth hormone (GH) secretion (A & B) and muscle-specific 
insulin-like growth factor-1 (muscle IGF-1) (C & D) correlated to the percentage of 
innervated neuromuscular junctions (% NMJ Innervation) in gastrocnemius muscles 
(A & C) and motor neuron number (Motor neuron count) in L2 – L6 of the lateral 
motor column (B & D) of aged C57Bl/6J mice at 104 weeks of age. Spearman 
correlation analysis was performed to assess the relationship between measures of 
total GH secretion following deconvolution analysis with percentage NMJ innervation 
and motor neuron count. Data for all parameters are summarised in table 6. 
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Table 6: Deconvoluted parameters of pulsatile growth hormone secretion in 
wild-type C57Bl/6J mice at 104 weeks of age, and the status of skeletal muscle 
innervation and motor neuron counts.  Histological data (motor neuron number 
and percent neuromuscular junction (NMJ) Innervation), deconvolution analysis and 
approximate entropy analysis parameters of pulsatile growth hormone (GH) 
secretion, and Spearman correlation analysis of deconvolution parameters of 
pulsatile GH secretion with percentage NMJ innervation of the gastrocnemius 
muscle, motor neuron number, and circulating and skeletal muscle-specific insulin-
like growth factor-1 (muscle IGF-1) in wild-type C57Bl/6J mice at 104 weeks of age. 
 
 
For GH, samples were collected at 10-minute intervals between 0700 hrs and 1300 hrs. Data are presented as 
mean ± SEM, * P ≤ 0.006 was considered significant when correlating %NMJ innervation and motor neuron 
number with deconvoluted parameters of pulsatile GH secretion, circulating IGF-1, and muscle IGF-1; n = 6. 
MPP, Mass per pulse. 
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7.5.3 Ageing is associated with accumulation of adiposity and increased insulin. 
Accumulation of perigonadal fat was observed throughout life, peaking at 52 weeks of age 
(fig. 32A). To further understand the implications of the increased adiposity in relationship 
to neuromuscular function, various energy metabolism-related hormones were also 
assessed, including leptin, insulin, and glucagon.  
Leptin is a lipid-derived hormone that is produced and secreted from adipose tissue 
in proportion to adiposity (JÉQuier, 2002). The primary function of leptin is to promote 
satiety in response to increased energy storage (i.e. fat), and regulates energy flux by 
maintaining energy intake proportional to adiposity (Berglund et al., 2012, Banks et al., 
2006). This control of energy expenditure is also achieved partially through regulating GH 
secretion (Watanobe and Habu, 2002). I demonstrated that leptin levels reflected the 
accumulation of perigonadal fat mass in an age-dependent manner through to 52 weeks of 
age (fig. 32B). Interestingly, leptin levels then gradually declined through to 104 weeks of 
age (fig. 32B).  
In addition to promotion of glucose storage (Kido et al., 2001, Plum et al., 2006, 
Koyama et al., 1997, Brehm et al., 2006, Rhodes and White, 2002), insulin also has 
conserved physiological functions to IGF-1 due to their structural similarities, including the 
promotion of cellular growth and survival, and the regulation of energy homeostasis (fig. 
2)(Párrizas et al., 1997, Chitnis et al., 2008, Valentinis et al., 2000, Ullrich et al., 1986, 
Rechler and Nissley, 1985). Insulin was observed to gradually increase throughout ageing 
(fig. 32C), reflecting and increased fat accumulation (fig. 32A). 
Glucagon is a peptide hormone that raises the concentration of 
circulating glucose during states of negative energy balance – in direct opposition to 
insulin -  and reduces fat storage (Liljenquist et al., 1974). The increase in glucose by 
glucagon is achieved by the breakdown of fats (lipolysis), similar to GH; glucagon levels 
may thus also affect fat utilisation (Liljenquist et al., 1974). My results revealed that 
glucagon levels remained unchanged throughout ageing (fig. 32D). These results suggest 
that the effects of glucagon on overall energy balance throughout ageing is negligible 
compared to GH.  
Taken together, these results were in line with the hypothesis that adiposity would 
increase throughout ageing, mirroring the decline in GH secretion (fig. 32; table 5).  
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Figure 32. Progressive increase in adiposity and insulin in wild-type C57Bl/6J 
mice throughout life. Perigonadal fat mass (A) accumulation was observed from 5 
through to 52 weeks of age, before peaking through to 104 weeks of age. Leptin 
levels (B) reflected the accumulation of perigonadal fat mass through to 52 weeks of 
age, before experiencing a gradual decline through to 104 weeks of age. Insulin 
levels (C) gradually increased from 5 through to 104 weeks of age. Glucagon 
remained unchanged from 5 through to 104 weeks of age. Values are expressed as 
mean ± SEM. A value of P ≤ 0.05 was accepted as significant; n = 6-9/group. 
 
7.5.4 Histological indicators of motor function not associated with adiposity and energy 
metabolism hormones in C57Bl/6J mice at 104 weeks of age. 
There was a significant correlation between pulsatile GH secretion, particularly parameters 
involving the amount of GH secreted in each pulse (i.e. total and pulsatile GH secretion, 
and MPP) with adiposity (table 7). Results also revealed no significant correlation between 
NMJ innervation and motor neuron number with any of the measures of adiposity and 
metabolic control (table 8).  
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Table 7: Deconvoluted parameters of pulsatile growth hormone secretion in 
wild-type C57Bl/6J mice at 104 weeks of age, and the status of adiposity. White 
adipose tissue (WAT) weight, deconvolution analysis and approximate entropy 
analysis parameters of pulsatile growth hormone (GH) secretion, and Spearman 
correlation analysis of deconvolution parameters of pulsatile GH secretion with WAT 
weight in C57Bl/6J mice at 104 weeks of age. 
 
 
 
For GH, samples were collected at 10-minute intervals between 0700 h and 1300 h. Data are presented as mean 
± SEM, *P ≤ 0.05 was considered significant; n = 6. MPP, Mass per pulse. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
113 
 
Table 8: Measures of adiposity and energy metabolism hormones in wild-type 
C57Bl/6J mice at 104 weeks of age, and the status of skeletal muscle 
innervation and motor neuron counts.  Histological data (motor neuron number 
and percent neuromuscular junction (NMJ) Innervation), white adipose tissue (WAT) 
weight, leptin, insulin, glucagon, and Spearman correlation analysis of adiposity and 
energy metabolism hormones with percentage NMJ innervation of the gastrocnemius 
muscle and lateral motor column motor neuron number in wild-type C57Bl/6J mice at 
104 weeks of age. 
 
Data are presented as mean ± SEM, *P ≤ 0.01 was considered significant; n = 6. 
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8 Chapter 8: Discussion – Part two 
8.1 Impaired growth hormone receptor signalling in SOD391 mice delays onset of motor 
function impairments without altering innervation. 
I previously revealed a significant positive correlation between GH secretion and skeletal 
muscle innervation in SOD mice at the onset of hindlimb weakness (fig. 15; table 2). It was 
ultimately suggested that the loss of innervation promoted the release of GH as a 
protective mechanism. Based on this theory, I hypothesised that impairments to GH-R 
signalling by the 391 mutation in SOD391 mice will hasten disease progression and 
reduce survival. However, my results revealed that the onset of hindlimb weakness was 
significantly delayed in SOD391-/- mice compared to SOD mice (fig. 24). Equally intriguing 
was that survival was unchanged despite the significant delay in onset (fig. 25). To 
understand this contradiction to my initial hypothesis, I assessed the histopathological 
hallmarks of ALS – skeletal muscle innervation and motor neuron numbers – in SOD391 
mice. No change to percent NMJ innervation in SOD391 mice was observed compared to 
SOD mice (fig. 26A), despite sustained motor neuron counts (fig. 26B). Together, these 
results implied that despite observing a protective role of GH against the development of 
motor impairments in SOD mice (fig. 15; table 2), impairing GH signalling actually delayed 
the onset of hindlimb weakness (fig. 24). However, these observations may not indicate 
conflicting results. Previous studies have provided evidence that increased adiposity and 
energy intake extends disease progression in ALS patients (Paganoni et al., 2011, Wills et 
al., 2014), and I suggested that the increased energy utilisation driven by the increased 
GH secretion may also adversely affecting pathology in SOD mice. Assessment of 
adiposity in SOD391 mice revealed a significant increase in subcutaneous fat at the latter 
stage of disease (fig. 27A), whereas SOD mice did not accumulate fat (fig. 27, A-C). This 
preservation of energy stores in the SOD391 mice may be a contributing factor to how the 
onset of hindlimb weakness is delayed by such a significant margin compared to SOD 
mice (fig. 24). Previous studies have demonstrated that a subset of ALS patients exhibit 
hypermetabolism (Funalot et al., 2009, Kasarskis et al., 1996, Desport et al., 2001, 
Bouteloup et al., 2009, Desport et al., 2005). Hypermetabolism is a generic term used to 
describe a significant increase in basal metabolic rate, which is the energy the body needs 
at rest (Mosby's dictionary of medicine, nursing & health professions / editors-in-chief, 
Peter Harris, Sue Nagy, Nicholas Vardaxis, 2010, Weissman and Kemper, 1992). 
Hypermetabolism is thus indicative of increased energy use. Therefore, I propose that the 
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increased energy stores may be beneficial in ALS by compensating for the increased 
energy demand. 
In order to maintain energy homeostasis, hypermetabolic individuals must increase 
energy intake to sustain energy stores – predominantly consisting of adipose fat (Felber 
and Golay, 1995). Interestingly, ALS patients do not increase food consumption despite 
hypermetabolism (fig. 33)(Kasarskis et al., 1996). This leads to a negative energy balance, 
which eventually leads to the decline in adiposity (fig. 33). Given that patients with greater 
BMI are associated with better prognoses (Paganoni et al., 2011), it would indicate that 
sustaining adiposity provides substantial benefits to ALS patients. This hypothesis is 
supported by evidence from the hSOD1G86R mouse model of ALS, where greater body 
weight and caloric intake slowed disease progression and extended survival (Dupuis et al., 
2004b). Consistently, caloric restriction in SOD mice hasten disease progression (Patel et 
al., 2010). Taken together, it is clear that energy demand in ALS patients is increased, and 
that the inability to meet these demands are detrimental to survival. The detrimental effects 
of fat loss introduces a conflict to the supposedly protective role of GH, as GH also 
reduces fat storage and raises overall energy utilisation (Møller and Jørgensen, 2009, 
Mavalli et al., 2010, Short et al., 2008, Bray, 1969, Rizza et al., 1982, Hussain et al., 1994, 
Trimble et al., 1980, Hansen et al., 1986, Bratusch-Marrain et al., 1982, Rizza, 1982, 
Meller et al., 1993, Dominici and Turyn, 2002, Bak et al., 1991). The increase in GH levels 
– either artificially via therapeutic intervention – implies that not only would there be an 
increase in anabolic and protective signals to skeletal muscle and neural tissue, but also 
increased energy expenditure and loss of adiposity. These conflicting actions may explain 
why GH treatment did not yield positive outcomes (Sacca et al., 2012, Smith et al., 1993). 
The current study was limited by not being able to determine energy expenditure in neither 
the SOD nor SOD391 mice, hence unable to draw conclusions to my hypothesis. Future 
studies will therefore need to determine the state of energy expenditure in relation to 
changes to energy storage, GH/IGF-1, and disease progression. 
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Figure 33. Pathophysiological changes in amyotrophic lateral sclerosis 
patients in relation to proximity of death. Amyotrophic lateral sclerosis (ALS) 
patients display gradual loss of adiposity (A). The reduction in adiposity coincides 
with an increase in resting energy expenditure, determined by the ratio of the 
measured energy expenditure (MEE) to the predicted resting energy expenditure 
(REE), using the Harris-Benedict equation (B). Daily energy consumption (C), 
however, remains unchanged and is below the recommended daily intake (%RDA). 
[Male: Blue; Female: red; Combined: black] (reproduced from Kasarskis et al., 1996). 
 
The underlying mechanism behind the delay in motor impairments in SOD391 mice is 
still unknown. The observation that skeletal muscle innervation is unchanged (fig. 26A) 
suggests that the delay in motor impairment is not due to the maintenance of 
neuromuscular connections. However, it was postulated that the protective effects of 
GH/IGF-1 were mediated through collateral axon sprouting. This adaptive process fails 
when a critical amount of motor neurons are lost, and the process becomes maladaptive, 
as surviving motor neurons form too many extra connections to neighbouring muscle fibres 
and become overloaded (Frey et al., 2000, Azzouz et al., 1997, Shefner and Gooch, 2002, 
Aggarwal and Nicholson, 2002, Hansen and Ballantyne, 1978, Gordon et al., 2004). The 
maintenance of motor neurons in SOD391 mice (fig. 26B) may therefore reduce the 
pressure imposed by collateral axon sprouting, thereby prolonging the development of 
motor impairments. However, this process does not address the loss of skeletal muscle 
innervations, which has been suggested to undergo degeneration through alternate 
pathological routes (Fischer et al., 2004, Dadon-Nachum et al., 2011). Therefore, 
regardless of the health of the surviving motor neurons, the loss of innervation ultimately 
leads to severe motor impairments and mortality; thereby no change in survival was 
observed. Ultimately, investigating the mechanism underlying the delay in motor 
117 
 
impairments in SOD391 mice in the future will provide insights into the role of GH in 
neurodegeneration in ALS. 
Finally, regardless of the underlying mechanism, GH-R impairment in SOD mice – 
which was presumed to abolish IGF-1 production (Rowland et al., 2005) – resulted in 
significant delays in the onset of motor impairments (fig. 24), significantly greater than that 
observed in SOD mice treated with exogenous GH (Chung et al., 2015) or increase IGF-1 
expression (Dobrowolny et al., 2005, Dodge et al., 2008). This significant increase in 
health span suggests a potential for inhibitors of GH/IGF-1 signalling, such as GH-R 
antagonists (Muller et al., 2004, Kopchick et al., 2002), in ALS therapy. 
 
8.2 Rise in growth hormone secretion is not inherent to the loss of innervation in non-
diseased wild-type C57Bl/6J mice, suggesting elevated growth hormone secretion is 
a pathological response in hSOD1G93A mice. 
The observation of correlations between pulsatile GH secretion and skeletal muscle 
innervation in SOD mice (fig. 15; table 2) raised the question of whether it was strictly a 
response to the pathological loss of innervation. To address this, I assessed GH/IGF-1 and 
adiposity in WT mice throughout ageing, and assessed their relationships with motor 
neuron numbers and skeletal muscle innervation. As all mammals were presumed to 
undergo an age-associated decline in neuromuscular function (Iannuzzi-Sucich et al., 
2002), the study into aged WT mice provided the opportunity to understand neuromuscular 
degeneration without disease or trauma. However, in order to do so, various parameters 
regarding ageing in WT mice needed to be characterised first in order to establish whether 
they were suitable models. I therefore conducted the first longitudinal assessment of 
pulsatile GH secretion in WT mice (or any mammal) throughout its natural lifespan. This 
characterisation of pulsatile GH secretion also laid one of the foundations necessary in 
understanding the relationship between GH and neuromuscular function in WT mice, as 
oppose to SOD mice or ALS patients. Gradual declines in pulsatile GH secretion were 
observed throughout the first 52 weeks of life (fig. 28; table 5). This decline in pulsatile GH 
secretion was accompanied by the decline in mIGF-1 (fig. 29B), supporting previous 
observations that mIGF-1 reflects GH levels (fig. 16B). At 104 weeks of age, muscle- 
specific IGF-1 levels were marginally increased relative to 78 weeks of age (fig. 29B), 
disrupting the pattern of gradual decline throughout life. Given that 104 weeks of age is 
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nearing the mean life expectancy of WT mice (Rowlatt et al., 1976), I hypothesised that 
this was associated with the deleterious effects of sarcopenia and loss of innervation to 
skeletal muscles. This hypothesis was seemingly supported by the subsequent 
observation that NMJ innervation at 104 weeks of age was significantly reduced (fig. 30A). 
However, no correlation was found between total GH secretion and muscle-specific IGF-1 
levels with NMJ innervation or motor neuron counts at 104 weeks of age in WT mice (fig. 
31; table 6). These results ultimately reveal that the GH-associated maintenance of 
innervation/reinnervation of skeletal muscles observed in SOD mice at the onset of 
disease (fig. 15; table 2) is not observed in aged WT mice undergoing age-associated loss 
of innervation. Curiously, circulating IGF-1 levels were unaltered throughout ageing (fig. 
29A), and did not reflect changes to GH (fig. 29; table 5) or mIGF-1 levels (fig. 29B), and 
suggests that despite reduced GH levels and significant declines in skeletal muscle 
innervation (fig. 30A), there is no feedback from IGF-1 to prompt the resurgence of GH. 
Taken together, these results support the hypothesis that the increase in GH secretion at 
the onset of motor impairments in SOD mice was a response to the pathological loss of 
innervation to skeletal muscles, and not an inherent physiological response to the loss of 
innervation. 
 
8.3 Histological indicators of motor function in aged wild-type mice is not associated with 
adiposity, suggesting that the reliance of hSOD1G93A mice on fat stores is a response 
to pathology. 
Previous studies have demonstrated that energy metabolism, particularly fat storage and 
energy intake, play a critical role in ALS pathology (Paganoni et al., 2011, Wills et al., 
2014). My previous results suggested that the increased GH secretion in SOD mice may 
have led to increased fat utilisation – thus reducing fat storage – following the onset of 
hindlimb weakness. This deleterious effect of GH was therefore hypothesised to be 
masking the beneficial anabolic effects of GH. This hypothesis was further supported when 
impairing GH signalling in SOD mice led to increased fat stores (fig. 27), accompanied by 
a delayed onset of motor impairments (fig. 24). Based on past observations that ALS may 
be associated with hypermetabolism, it was proposed that SOD mice may become reliant 
on fat stores to compensate for increased energy demands. To better understand the 
association between motor function and adiposity, and determine whether the observed 
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dependence on fat was due to pathology, I first investigated the physiological relationship 
between pulsatile GH secretion and adiposity in further detail. Although the relationship 
between GH and adiposity is well established (Møller and Jørgensen, 2009, Mavalli et al., 
2010, Short et al., 2008, Bray, 1969), more detailed understanding between the 
deconvoluted parameters of pulsatile GH secretion outlined in my study may reveal hidden 
relationships that will benefit not only ALS research, but endocrinology as a whole. Results 
revealed that GH secretion is significantly correlated to WAT weight in WT mice at 104 
weeks of age (table 7), providing support that adiposity is strongly tied to GH secretion 
even at old age under physiological conditions. I then further assessed the relationship 
between the histological indicators of motor function – skeletal muscle innervation and 
motor neuron numbers – and measures of adiposity and related hormonal regulators – 
WAT, leptin, insulin, and glucagon – in ageing WT mice (table 8), and revealed age-
associated increases in WAT, leptin, and insulin. Glucagon levels were also assessed to 
better understand the factors directly influencing energy utilisation in the mice (fig. 32D), in 
addition to GH and insulin. Results revealed no significant alterations to glucagon levels 
throughout life (fig. 32D), indicating it is not involved in the age-dependent accumulation of 
WAT throughout life. These results also strengthens the claim that GH is the main driver of 
fat utilisation in these animals. Finally, correlation analyses also revealed no significant 
associations between skeletal muscle innervation and motor neuron counts with WAT, 
leptin, insulin, nor glucagon at 104 weeks of age – an age where the loss of innervation is 
significant (table 8). Previous observations in both SOD and SOD391 mice revealed that 
the alteration to neuromuscular function was associated with changes to adiposity (fig. 27), 
which suggested that the pathological neurodegeneration forced the animals to become 
dependent on fat. As this was not observed in the WT mice despite significant losses to 
skeletal muscle innervation (fig. 32A; table 8), these results ultimately reveal that the 
reliance on fat observed in SOD mice following the onset of motor impairments was a 
result of the ALS-like pathology experienced by SOD mice, and not inherent to the loss of 
innervation. 
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9 Chapter 9: Conclusions, limitations, and significance 
9.1 Summary and conclusions 
The aim of this thesis was to investigate the role of growth hormone (GH) in amyotrophic 
lateral sclerosis (ALS). Given that past studies have shown evidence of GH deficiency in 
ALS patients, it was hypothesised that the hSOD1G93A (SOD) mouse model of ALS would 
have reduced pulsatile GH secretion levels during the symptomatic stages of disease – a 
hallmark of ALS pathology. As hypothesised, a reduction in GH secretion was observed in 
SOD mice at the end-stage of disease, which established the SOD mouse as an 
appropriate model to study the GH-related changes associated with ALS. However, GH 
secretion increased significantly upon the onset of hindlimb weakness in SOD mice, a 
novel finding that indicated that the role of GH in ALS is dynamic, and contributes to the 
degenerative disease in more complex ways than just a reduction in anabolic signalling. 
This increase in GH secretion at the onset of hindlimb weakness was associated with 
skeletal muscle innervation, and was hypothesised to be a protective mechanism against 
the loss of innervation. The underlying mechanism was hypothesised to be the induction of 
collateral axon sprouting – an adaptive process whereby motor neurons reinnervate 
neuromuscular junctions lost due to neurodegeneration – possibly by stimulating the local 
production of insulin-like growth factor-1 (IGF-1) in skeletal muscles. To determine whether 
GH was protective, GH signalling was impaired in SOD mice via cross-breeding with 
transgenic mice with truncated GH receptors (GH-Rs). Impairing GH signalling in SOD 
mice delayed the onset of hindlimb weakness, but did not extend survival. The delay in 
hindlimb weakness was attributed to the maintenance of motor neurons in the lumbar 
spinal cord. It was hypothesised that the maintenance of motor neurons sustained 
healthier neuromuscular function by preventing motor neurons from becoming overloaded; 
prolonging the adaptive stage of collateral axon sprouting. The maintenance of fat stores 
appeared to be a prominent factor in the maintenance of motor neuron numbers, 
supporting past studies indicating that increased energy intake and storage are beneficial 
in ALS. However, these protective processes ultimately cannot prolong survival as 
innervation loss continued. To differentiate whether my observations were due to 
pathology, aged WT mice were employed as a model of non-pathological loss of 
neuromuscular function. Advance aged WT mice at the end of their life expectancy 
experienced significant loss of skeletal muscle innervation, but not the compensatory 
increase in GH secretion as seen in SOD mice at the onset of hindlimb weakness. 
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Furthermore, adiposity was also not associated with the loss of motor neurons. Taken 
together, these findings suggested that the increase in GH secretion and apparent 
dependency on fat stores are all responses to the ALS-like pathology experienced by SOD 
mice. 
 
9.2 Significance 
This thesis presents the first comprehensive assessment of pulsatile GH secretion 
throughout disease progression in SOD mice, which lays the foundations for future studies 
into the endocrinology of ALS. Through this I also revealed that the response of GH 
secretion to disease progression in SOD mice is dynamic, and GH deficiency only occurs 
at the latter stage of disease. More striking is the finding that GH secretion increases at the 
onset of hindlimb weakness, which further illustrates the dynamic change of the role GH 
plays throughout different stages of disease in ALS. More importantly, this finding reveals 
that ALS is not only characterised by a reduction in anabolic signalling, but that GH also 
acts as an intrinsic protective agent against the development of motor impairments. 
Finally, the significant increase in GH secretion may also be used to aid in the early 
detection of ALS or used as a prognostic marker, which are currently extremely limited. 
This could be applied either by direct measures of GH, or its associated factors, such as 
IGF-1 or changes to energy metabolism. 
My study is the first to highlight the conflict of GH being utilised in a protective mechanism 
against innervation loss in ALS, but also the importance of fat stores to sustain motor 
function – which is possibly utilised and lost at an accelerated rate in response to the 
increased secretion of GH. Targeting specifically at the anabolic effects of GH/IGF-1 while 
maintaining adiposity is therefore the next step in uncovering the applications of GH as a 
therapeutic agent for ALS. However, given that there is currently no effective treatment for 
ALS, the finding that GH signalling suppression prolongs health span in SOD mice may be 
utilised in the short term to alleviate the paralytic symptoms of ALS patients, such as the 
use of GH-R antagonists. 
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